

# 1 Single-cell atlas of transcriptomic vulnerability 2 across multiple neurodegenerative and 3 neuropsychiatric diseases

4

## 5 **Authors**

6 Donghoon Lee<sup>†#1,2,3,4</sup>, Mikaela Koutrouli<sup>#1,2,3,4,5</sup>, Nicolas Y. Masse<sup>#1,2,3,4</sup>, Gabriel E. Hoffman<sup>#1,2,3,4,6,7</sup>, Seon  
7 Kinrot<sup>1,2,3,4</sup>, Xinyi Wang<sup>1,2,3,4</sup>, Prashant N.M.<sup>1,2,3,4</sup>, Milos Pjanic<sup>1,2,3,4</sup>, Tereza Clarence<sup>1,2,3,4</sup>, Fotios Tsetsos<sup>1,2,3,4,6</sup>,  
8 Deepika Mathur<sup>1,2,3,4,6,7</sup>, David Burstein<sup>1,2,3,4,6,7</sup>, Karen Therrien<sup>1,2,3,4</sup>, Aram Hong<sup>1,2,3,4</sup>, Clara Casey<sup>1,2,3,4</sup>, Zhiping  
9 Shao<sup>1,2,3,4</sup>, Marcela Alvia<sup>1,2,3,4</sup>, Stathis Argyriou<sup>1,2,3,4</sup>, Jennifer Monteiro Fortes<sup>1,2,3,4</sup>, Pavel Katsel<sup>3</sup>, Pavan K.  
10 Auluck<sup>8</sup>, Lisa L. Barnes<sup>9,10</sup>, Stefano Marengo<sup>8</sup>, David A. Bennett<sup>9,10</sup>, PsychAD Consortium<sup>11</sup>, Lars Juhl Jensen<sup>5</sup>,  
11 Kiran Girdhar<sup>1,2,3,4</sup>, Georgios Voloudakis<sup>1,2,3,4,6,7,12</sup>, Vahram Haroutunian<sup>2,3,7,13</sup>, Jaroslav Bendl<sup>1,2,3,4</sup>, John F.  
12 Fullard<sup>#1,2,3,4</sup>, Panos Roussos<sup>†#1,2,3,4,6,7</sup>

13

## 14 **Affiliations**

15 1 Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.  
16 2 Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.  
17 3 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.  
18 4 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,  
19 USA.  
20 5 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of  
21 Copenhagen, Copenhagen, Denmark.  
22 6 Center for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx,  
23 NY, USA.  
24 7 Mental Illness Research, Education and Clinical Center VISN2, James J. Peters VA Medical Center, Bronx,  
25 NY, USA.  
26 8 Human Brain Collection Core, National Institute of Mental Health-Intramural Research Program, Bethesda,  
27 MD, USA.  
28 9 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.  
29 10 Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.  
30 11 [PsychAD Consortium](#)  
31 12 Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York,  
32 NY, USA.  
33 13 Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

34

35 # These authors contributed equally to this work.

36 † Corresponding author: [donghoon.lee@mssm.edu](mailto:donghoon.lee@mssm.edu); [panagiotis.roussos@mssm.edu](mailto:panagiotis.roussos@mssm.edu)

## 37 **Abstract**

38 Neurodegenerative and neuropsychiatric diseases impose a significant societal and public health burden.  
39 However, our understanding of the molecular mechanisms underlying these highly complex conditions remains  
40 limited. To gain deeper insights into the etiology of different brain diseases, we used specimens from 1,494  
41 unique donors to generate a population-scale single-cell transcriptomic atlas of the human dorsolateral  
42 prefrontal cortex (DLPFC), comprising over 6.3 million individual nuclei. The cohort includes neurotypical  
43 controls as well as donors affected by eight common and complex brain disorders: Alzheimer's disease (AD),  
44 diffuse Lewy body disease (DLBD), vascular dementia (Vas), Parkinson's disease (PD), tauopathy,  
45 frontotemporal dementia, schizophrenia, and bipolar disorder. We show that inter-individual variation accounts  
46 for a substantial portion of gene expression variation in the DLPFC. By comparing transcriptomic variation  
47 across diseases, we reveal universal signatures enriched in basic cellular functions such as mRNA splicing  
48 and protein localization. After discounting these cross-disease signatures, we show strong genetic and  
49 transcriptomic concordance among AD, DLBD, Vas, and PD, largely driven by alteration of synaptic signaling  
50 functions in neurons. Furthermore, we characterize transcriptomic variation among different AD phenotypes  
51 that were distinct from healthy aging. We uncover mitigating effects of interneurons and aggravating effects of  
52 immune and vascular cells in AD dementia. Further exploring the effect of the neuropsychiatric symptoms  
53 frequently accompanying AD, we identify a link to deep layer excitatory neurons. By constructing transcriptome  
54 trajectories that capture AD progression, we show cell-type specific responses implicated in early and late  
55 stages of AD. Our atlas provides an unprecedented perspective of the transcriptomic landscape in  
56 neurodegenerative and neuropsychiatric diseases, shedding light on shared and distinct processes involving  
57 the neuro-immune-vascular systems, and identifying potential targets for therapeutic intervention.

## 58 **Main**

59 The human brain is a highly complex organ composed of billions of functionally diverse cells. Under  
60 pathogenic stress, cellular and molecular responses are often convoluted and contextual, so understanding  
61 their dysfunction in disease is challenging. Recent work has begun to unravel the molecular changes that  
62 occur at the single-cell level, which has been particularly helpful in understanding the vulnerability of specific  
63 cell types in various disease contexts, as well as the complex interplay between different cell types. In  
64 Alzheimer's disease (AD), it has been shown that a thorough exposition of cellular heterogeneity in the brain,  
65 the coordinated interactions between neurons and glia, and the selective depletion of vulnerable inhibitory  
66 neuronal subtypes are critical for understanding AD pathology<sup>1,2</sup>.

67 Building a large-scale disease atlas at single-cell resolution creates an unprecedented opportunity to  
68 understand molecular responses at the cellular level and estimate population-level variation in the brain  
69 transcriptome. A large sample size provides the resolution needed to establish robust basal-level conditions  
70 and to sufficiently capture the full spectrum of disease pathology. By leveraging cross-disease atlases, studies  
71 have revealed shared and distinct patterns of gene-expression perturbations in major psychiatric diseases as  
72 well as shared genetic factors leading to molecular convergence<sup>3,4</sup>. As such, characterizing shared  
73 transcriptomic vulnerabilities and pathophysiology together has significant implications for early treatment and  
74 the development of effective therapeutics.

75 Here, we introduce the PsychAD cohort, which consists of 1,494 unique brain donors affected by various  
76 neurodegenerative and neuropsychiatric diseases in addition to neurotypical controls. The resulting single-  
77 nucleus RNA sequencing (snRNA-seq) dataset in the dorsolateral prefrontal cortex (DLPFC) of those donors,  
78 comprising over 6.3 million nuclei representing 27 distinct subclasses of cells, is sufficiently-powered to identify  
79 molecular signatures from multiple traits while accounting for individual variation. We utilize this dataset to  
80 uncover shared transcriptomic vulnerability across these diseases and, in so doing, to better understand  
81 specific transcriptional patterns and regulatory drivers underpinning each trait. By characterizing putative  
82 disease-driving molecular changes across multiple traits, we differentiate shared and novel disease- and cell  
83 type-specific associations. Concordance between heritability estimates and transcriptomic similarity identifies  
84 shared genetic factors underlying cross-disorder traits. Deep phenotyping of AD trajectories using Tau  
85 pathology and clinical dementia status suggests a potential link between immune and brain vasculature  
86 dysfunctions. In summary, our study provides a rich and comprehensive resource for exploring the cellular and  
87 molecular mechanisms of brain function and dysfunction across multiple neurodegenerative and  
88 neuropsychiatric diseases.

## 89 **The PsychAD cohort represents diverse neurodegenerative and** 90 **neuropsychiatric diseases across the lifespan**

91 The PsychAD cohort comprises 1,494 unique brain donors (**Fig. 1a, Supplementary Table 1**). Brain tissue  
92 specimens were obtained from three sources: 1,042 donors from Mount Sinai NIH Neurobiobank (MSSM), 300  
93 from Human Brain Collection Core (HBCC), and 152 from Rush Alzheimer's Disease Center (RADC). The  
94 cohort covers the whole lifespan of postnatal ages between 0 and 108, roughly equal numbers of males and  
95 females, and represents a diverse range of disease phenotypes, including Alzheimer's disease (AD), diffuse  
96 Lewy body disease (DLBD), vascular dementia (Vas), tauopathy (Tau), frontotemporal dementia (FTD),  
97 Parkinson's disease (PD), schizophrenia (SCZ), and bipolar disorder (BD). The cohort covers a diverse genetic  
98 background and over 30% of the donors were of non-European (EUR) ancestry.

99 We streamlined the unified processing of the data as well as the harmonization of clinical, and technical  
100 metadata (**Fig. 1b, Supplementary Fig. 1a, Methods**). Frozen brain specimens were randomized and  
101 processed in batches of 6. Equal numbers of nuclei from each sample were pooled together and each pool

102 was subjected to snRNA-seq twice to generate a technical replicate. Following quality control (**Supplementary**  
103 **Figs. 1c-i**), the final data sets consisted of 6,320,459 nuclei. To characterize transcriptomic vulnerability across  
104 multiple neuropsychiatric and neurodegenerative diseases, we organized the analysis into three tiers.


105 First, we focused on the cross-disorder analyses (**Fig. 1c**). We targeted six neurodegenerative diseases  
106 (NDDs, including AD, DLBD, Vas, Tau, FTD, and PD) and two neuropsychiatric diseases (NPDs, including  
107 SCZ and BD), using a subset of 1,160 donors with minimal comorbidity aged  $\geq 17$ . To estimate the sharing of  
108 transcriptomic vulnerability, we compared donors affected with NDDs and NPDs against the baseline of 319  
109 neurotypical controls.

110 The second-tier analysis focused on the stage of AD progression based on pathological and cognitive  
111 impairment measures using a subset of 696 individuals (**Fig. 1d**). To uncover cell-type-specific roles in disease  
112 onset and disease trajectory, we compared two characteristic neuropathological abnormalities of the AD brain:  
113 the accumulation of amyloid- $\beta$  ( $A\beta$ ) plaques measured using CERAD plaque density score and tau-based  
114 neurofibrillary tangle (NFT) pathology measured using Braak staging, along with cognitive impairment.

115 In the third tier, we surveyed neuropsychiatric symptoms (NPS) within 234 individuals affected by AD  
116 pathology (**Fig. 1e, Supplementary Fig. 1b**). NPS are core features of AD and are common in patients with  
117 dementia<sup>5</sup>. We broadly categorized NPS into three groups, (1) depression or mood-related, (2) weight loss or  
118 psychomotor agitation (PMA), and (3) weight gain, insomnia, or suicidal ideation, based on co-occurrence  
119 estimates, sharing molecular mechanisms that lead to increased prevalence with disease severity.

120





\*54 donors with incomplete pathology or cognitive status omitted

122 **Fig. 1. Overview of the PsychAD cohort and study design. (a)** Breakdown of donors by tissue source,  
123 number of diagnoses, genetic ancestry, distribution of age at death, sex, and % availability of genotype data.  
124 **(b)** Data generation and analysis workflow. **(c)** A subset of the PsychAD cohort (n=1,160 donors) focused on  
125 cross-disorder contrasts. This subset includes a group of neurotypical controls that were used to compare  
126 against 8 neurodegenerative and neuropsychiatric disorders. UpSet plot describing available disease  
127 phenotypes and number of unique donors by brain bank. **(d)** A subset of the PsychAD cohort (n=696 donors)  
128 focused on AD phenotype contrasts. Comparison of different measures of AD severity, including neuritic  
129 plaque density (CERAD), neurofibrillary tangle (NFT) pathology, and cognitive impairments. \*n=54 donors with  
130 incomplete pathology or cognitive status were omitted from the figure. **(e)** A subset of the PsychAD cohort  
131 (n=234 donors) was used to characterize single-cell transcriptomic changes underlying NPS in AD. AFR:  
132 African, AMR: Ad Mixed American, EAS: East Asian, SAS: South Asian, EUR: European, NPS:  
133 Neuropsychiatric Symptom, PMA: Psychomotor Agitation, PMR: Psychomotor Retardation.

## 134 **Unified processing and hierarchical cellular taxonomy of the human** 135 **prefrontal cortex uncovers 27 distinct subclasses of cells**

136 To understand heterogeneous human cortical tissues in disease contexts, we require a cell type taxonomy  
137 that is robust to aging, disease phenotypes, and various sampling and technical biases. Following unified  
138 computational processing, quality controls, and batch normalization of snRNA-seq libraries representing 1,494  
139 dissections, processed in duplicate (**Methods**), we annotated cell types of the human DLPFC using the cell  
140 taxonomy of the primate DLPFC<sup>6</sup> and human primary motor cortex<sup>7</sup> as a baseline reference. The resulting  
141 human DLPFC cellular taxonomy was organized using three levels of hierarchy, identifying 8 broad cell  
142 classes, 27 subclasses, and 65 functionally distinct subtypes (**Fig. 2a, Supplementary Table 2**). Each level of  
143 the annotation hierarchy represents a slice in the clustering dendrogram. At the top, the “class level” of the  
144 annotation hierarchy defines 8 major cell types, including two broad neuronal cell types: glutamatergic  
145 excitatory (EN) and GABAergic inhibitory neurons (IN), three glial: astrocytes (Astro), oligodendrocytes (Oligo),  
146 and oligodendrocyte progenitor cells (OPC), and three non-neuronal cell types: immune cells (Immune), mural  
147 and vascular cells (Mural), and endothelial cells (Endo). Subsequent levels of the annotation hierarchy,  
148 subclasses and subtypes, were derived by iteratively re-clustering the subset of cells by gene matrix using a  
149 new set of variable genes relevant to the particular cell type (see *iterative clustering* in **Methods**). The subclass  
150 level distinguished the EN class into 10 subclasses and the IN class into 7 subclasses (**Supplementary Figs.**  
151 **2c,d**). Different types of neurons, especially ENs, are organized into six horizontal layers (L1-L6) that are  
152 distinct in both cytoarchitecture and function<sup>8</sup>. *In situ* spatial transcriptomics data was used to confirm that the  
153 EN subclasses were spatially distinct and found in their respective neocortical layers (**Fig. 2b**). The EN  
154 subclasses were denoted by their laminar organization (L2-6) and axon projection characteristics (IT: intra-  
155 telencephalic, ET: extra-telencephalic, NP: near projecting, CT: corticothalamic, and L6B). IN subclasses were  
156 determined using their characteristic marker genes (**Figs. 2c,d**); Ivy cells (IN\_LAMP5\_LHX6), neurogliaform  
157 cells (IN\_LAMP5\_RELN), basket cells (IN\_PVALB), chandelier cells (IN\_PVALB\_CHC), Martinotti and non-  
158 Martinotti cells (IN\_SST), VIP (IN\_VIP), and homologs of mouse Sncg inhibitory neurons<sup>6</sup> (IN\_ADARB2).  
159 Unlike laminar organization of EN, IN subclasses were distributed randomly throughout the gray matter, except  
160 for IN\_ADARB2, which was predominantly found in the superficial layer of the neocortex (**Supplementary Fig.**  
161 **2e**). Some previously annotated rare inhibitory neuron types, like SST NPY or SST HGF, were not  
162 distinguished at the subclass level, but were identified at the subtype level. The cellular taxonomy was  
163 relatively consistent, and the subtypes were well represented across all three brain sources (**Supplementary**  
164 **Figs. 2a,b**). Neuronal cells made up 38.4% (EN 23.0% and IN 15.4%), with oligodendrocytes being the next  
165 most abundant, at 36.1%. Major cell types matched well when compared to the previous cellular taxonomy of  
166 DLPFC<sup>1,6</sup>, and subtypes were relatively concordant (**Supplementary Figs. 2f-h**). Neuronal subclasses exhibit

167 distinct functional characteristics from non-neuronal subclasses (**Fig. 2e**). ENs are enriched in pathways  
168 associated with synaptic vesicle priming and neurotransmitter secretion, whereas INs are enriched with  
169 functions related to receptor signaling and ion transport. Immune cell types show unique enrichments in  
170 functions related to cytotoxic immune responses, while mural cells are involved in vessel morphogenesis. It  
171 has been shown cell types are differentially implicated in mediating disease risks<sup>9,10</sup>. Therefore, we further  
172 annotated cell types with disease GWASs using the single-cell disease-relevance score (scDRS) and found  
173 that neurological diseases largely involve immune and glial cell types, whereas psychiatric diseases are  
174 predominantly associated with neuronal cell types (**Fig. 2f, Supplementary Fig. 2i**).  
175





177 **Fig. 2. Unified processing of the single-cell transcriptomics atlas and hierarchical cellular taxonomy.**  
178 **(a)** Hierarchical structure of transcriptome-based cellular taxonomy. Taxonomic annotation at three levels of  
179 granularity; class (n=8), subclass (n=27), and subtype (n=65). **(b)** Spatial distribution of major cell classes. **(c)**  
180 Spatial distribution of EN subclasses. **(d)** Markers defining neuronal subclasses. **(e)** Functional enrichment of  
181 cellular subclasses using Gene Ontology Biological Process (GO BP). **(f)** Enrichment of heritable traits for  
182 cellular subclasses using previous GWAS studies (scDRS). AD<sup>11</sup>, MS: multiple sclerosis<sup>12</sup>, PD<sup>13</sup>, Epilepsy:  
183 epilepsy focal<sup>14</sup>, Migraines<sup>15</sup>, Stroke<sup>16</sup>, ALS: amyotrophic lateral sclerosis<sup>17</sup>, SCZ<sup>18</sup>, BD<sup>19</sup>, MDD: major  
184 depressive disorder<sup>20</sup>, ASD: autism spectrum disorder<sup>21</sup>, ADHD: attention deficit hyperactivity disorder<sup>22</sup>,  
185 Insomnia<sup>23</sup>, Education: educational attainment<sup>24</sup>, IQ: intelligence<sup>25</sup>, Alcoholism<sup>26</sup>, OCD: obsessive compulsive  
186 disorder<sup>27</sup>, Tourettes: Tourette Syndrome<sup>28</sup>, Obesity<sup>29</sup>, T2D: type 2 diabetes mellitus<sup>30</sup>, Cholesterol: cholesterol  
187 total<sup>31</sup>, RA: rheumatoid arthritis<sup>32</sup>, IBD: inflammatory bowel disease<sup>33</sup>, UC: ulcerative colitis<sup>34</sup>.


## 188 **Inter-individual variation of the human cortical transcriptome**

189 Population-level transcriptomic variation is influenced by genetic differences among individuals,  
190 phenotypes such as age, sex, and disease status, as well as technical factors such as tissue source,  
191 dissection bias, and single-cell library preparation. We first set out to explore the determinants of the overall  
192 transcriptome variation in our sample cohort. Population-scale snRNA-seq data allowed partitioning of the  
193 gene expression variance by cellular variables (including cell type and fraction of mitochondrial and ribosomal  
194 genes), donor-level variables (including subject ID, age, sex, genetic ancestry, and diagnosis), and technical  
195 variables (including source of the tissue specimen, post-mortem interval, technical replicates, and sequencing  
196 depth) (**Fig. 3a**). Across all genes, a mean of 49.8% of the total expression variance can be attributed to  
197 variation across cell type, while inter-individual variation explains 9.8%, and unexplained residual variation  
198 accounts for 38.9%. The remaining variables explained less than 1% of the total variance on average. We  
199 prioritized several drivers of expression variation (**Fig. 3b**). Several genes with high cell type variation  
200 (including ATP8A2, GABRB3, and DOCK3) are dominated by genes differentially expressed between neuronal  
201 and non-neuronal cell types (**Fig. 3c**). As expected, genes varying across sexes were located in sex  
202 chromosomes (**Supplementary Fig. 3c**). Interestingly, genes with high variation across tissue sources were  
203 mostly mitochondrial genes (**Supplementary Fig. 3d**), possibly due to technical differences in physiological  
204 and environmental factors from dissection and handling at the respective tissue sources<sup>35,36</sup>. Top 3 genes with  
205 the highest variation across diagnosis (CIRBP, FGF1, and WSB1) were implicated in stress response and  
206 hypoxia. CIRBP, which also had a high variation across PMI (ranked 4th), was a gene induced in response to  
207 low temperature and hypoxia, and its expression was inversely associated with patient survival in cancer<sup>37</sup>.  
208 FGF1 was another gene linked to temperature stress and hypoxia<sup>38</sup>, and WSB1 was a neuroprotective protein  
209 and regulator of many genes associated with the cellular response to hypoxia<sup>39</sup>. Top variable gene in PMI,  
210 HP1BP3, was chromatin organizing protein induced in hypoxic conditions<sup>40</sup>. This analysis examines expression  
211 variation shared across cell types, so the low variance fraction explained by diagnosis indicates the need for  
212 cell type specific analysis.

213 We observed that inter-individual differences explained 80.9% of the variation in ARL17B gene expression  
214 (**Fig. 3b,d**). Several adjacent genes, such as ARL17A and KANSL1, also have high inter-individual variation  
215 and are localized on the disease-associated MAPT locus (17q21.31) (**Fig. 3b**). ARL17B and KANSL1 are often  
216 found as a fusion transcript (KANSL1::ARL17B) and frequently undergo polymorphic translocation<sup>41,42</sup>, and  
217 they have been implicated in neurological disorders such as ALS, PD, and MS<sup>43-45</sup>. To interrogate possible  
218 genetic causes for variation in expression, we examined normalized gene expression at the donor level,  
219 stratified by MAPT haplotypes (**Fig. 3e, Methods**). We observed two distinct patterns of ARL17B expression  
220 that could be potentially linked to H1 and H2 MAPT haplotypes, with lower expression linked to the H1H1  
221 genotype. We observed stratification of haplotypes by genetic ancestry, where the H2H2 genotype was almost

222 exclusively found within EUR ancestry, consistent with previous reports<sup>46</sup> (**Supplementary Fig. 3f**). We  
223 replicated a previous finding that the H1 haplotype is associated with PD susceptibility, and observed that the  
224 H1H1 genotype increases PD risk with an odds ratio (OR) of 4.125 (**Supplementary Fig. 3g**;  $P \leq 0.0273$ ),  
225 much higher than previously reported (1.42<sup>47</sup> or 1.46<sup>48</sup>). In addition, we tested the contribution of the H1  
226 haplotype to AD among non-ApoE4 carriers<sup>49</sup> but did not find a significant association ( $P \leq 0.302$ ). The  
227 variation in inter-individual expression is inversely correlated with genetic constraints, as measured by the  
228 gnomAD Loss-of-function Observed/Expected Upper-bound Fraction (LOEUF) score (**Fig. 3f, Supplementary**  
229 **Fig. 3h**). Genes with high inter-individual variability tend to be less constrained and are often associated with  
230 the maintenance of basal cellular functions (i.e., housekeeping genes), including translation, RNA processing,  
231 metabolism, signal transduction, and structural maintenance, consistent with previous findings<sup>50,51</sup> (**Fig. 3g**).  
232






234 **Fig. 3. Sources of transcriptomic variation.** (a) Variance partition of the transcriptome. (b) Top genes for  
 235 each technical and clinical covariate category. (c) ATP8A2 gene expression across cell types. (d) ARL17B  
 236 gene expression across donors. (e) Stratification of ARL17B expression by MAPT haplotypes. (f) Genetic  
 237 constraints of gene groups measured by average LOEUF score (upper bound of 90% confidence interval for  
 238 o/e ratio for high confidence pLoF variants; lower values indicate more constrained). “Low”, indicates the  
 239 bottom 2,000 genes with the lowest brain donor variance. “High”, indicates the top 2,000 genes with the  
 240 highest brain donor variance. “Random”, indicates 2,000 random genes that are in neither the “Low” nor “High”  
 241 category. (g) Functional enrichment for genes with high or low inter-individual variation.

## 242 **Cross-disorder variation of cell type composition across 8 different** 243 **neurodegenerative and neuropsychiatric diseases**

244 Utilizing 318 neurotypical donors as a baseline, we systematically evaluated variation in the cellular  
 245 composition of the DLPFC across eight different neurodegenerative (NDDs, including AD, DLBD, Vas, Tau,  
 246 PD, and FTD) and neuropsychiatric diseases (NPDs, including SCZ and BD). Using all subclass-level cell  
 247 types, we found the overall cell type composition changes were broadly stratified by NDDs and NPDs, and that  
 248 they form distinct clusters (**Fig. 4a**). Notably, we observed a higher degree of similarity among AD, DLBD, and  
 249 Vas. Focusing solely on neurons, we saw equal or greater correlations among the same class of diseases,  
 250 underscoring the critical role of neurons in the etiology of neurological diseases. Additionally, similarities  
 251 between FTD-AD (all cells) and FTD-Tau (neurons) were observed. Exploring each subclass further, we  
 252 identified a notable overlap in the prevalence of neuronal and glial cell types within the same class of diseases  
 253 (**Fig. 4b, Supplementary Table 3**). Specifically, we observed that NDDs were characterized by a higher  
 254 abundance of non-neuronal cells, particularly vascular cell types (**Supplementary Fig. 4c**), as well as  
 255 elevation of a specific IN, namely IN\_LAMP5\_RELN, IN\_LAMP5\_LHX6, and IN\_ADARB2 subclasses. In  
 256 contrast, NPDs were predominantly associated with an increase in neuronal cells, particularly deep layer ENs  
 257 in L5-6. To further identify specific subtypes responsible for driving the compositional changes in vascular cell  
 258 types, we used subtype-level annotation to analyze compositional variation in 8 NDDs and NPDs (**Fig. 4c,**  
 259 **Supplementary Fig. 4d**). From this, we identified dominant subtypes of each subclass that further  
 260 differentiated NDDs and NPDs. For example, vascular leptomenigeal cells (VLMCs) are barrier-forming  
 261 fibroblasts of the brain<sup>52</sup>, and they are transcriptionally segregated into three subtypes; two meningeal VLMCs  
 262 (VLMC\_DCDC2 and VLMC\_SLC4A4) and one perivascular VLMC (VLMC\_ABCA6). Our subtype-level  
 263 analysis indicates a polarized response of meningeal VLMC\_DCDC2 where their increased proportions are  
 264 specifically associated with most NDDs.  
 265




267 **Fig. 4. Cross-disorder variation of cell type composition comparing 8 different NDDs (AD, DLBD, Vas,**  
268 **Tau, PD, and FTD) and NPDs (SCZ and BD) against common neurotypical controls. (a)** Correlation of cell  
269 type composition using all cell types (bottom-left triangle) or limited to neuronal cell types (upper-right triangle).  
270 **(b)** Variation in cell type composition for each subclass in 8 different diseases. NDDs and NPDs indicate meta-  
271 analysis using broad disease categories. **(c)** Variation of subtype-level composition in the vascular cell class.  
272 Color intensity indicates effect size and dot size reflects the statistical significance of correlations.

## 273 **Cross-disorder variation of gene expression and genetic concordance**

274 Cross-disorder gene expression analysis has the potential to identify shared biological pathways and  
275 mechanisms, improve diagnostic accuracy, and help develop targeted treatments. To assess the extent of  
276 sharing between NDDs and NPDs, we performed a comprehensive analysis of differentially expressed genes  
277 (DEGs) by decomposing the total disease signatures into shared and distinct components. Using Dreamlet  
278 followed by Mashr<sup>53</sup>, we performed composite tests to evaluate the specificity of disease effect (**Methods**),  
279 leading to the identification of shared disease signatures that are invariant across cell subclasses (**Fig. 5a,**  
280 **Supplementary Figs. 5a,b**). Genes sharing cross-disorder signatures encompassed crucial transcriptional  
281 processes, such as mRNA splicing and processing, and protein localization to mitochondria. The observed  
282 cross-disorder signatures, affecting genes, which are critical for the proper functioning of cellular processes,  
283 align with the omnigenic model<sup>54</sup>, and further support the pleiotropy of those genes influencing multiple  
284 disorders, both genetically and transcriptionally. After discounting the shared cross-disorder signatures from  
285 the overall DEG expression profiles, we used the residual effects to quantify the pair-wise transcriptomic  
286 similarity between traits (**Fig. 5b, Supplementary Table 4**). Similarities between pairs of NDDs or NPDs were  
287 greater compared to the NDD-NPD contrast, with AD, DLBD, Vas, and PD being the most similar. Meta-  
288 analysis using disease-specific effects of these four transcriptomically similar traits (AD, DLBD, Vas, and PD)  
289 implicated neuronal development and synaptic signaling pathways involving interneurons (IN\_LAMP5\_RELN,  
290 IN\_ADARB2, and IN\_PVALB) as well as vasculature development from the VLMC subclass (**Fig. 5c,**  
291 **Supplementary Fig. 5c**).

292 Comparison of pairwise trait co-heritability against pairwise transcriptome similarity can identify shared  
293 genetic influences and underlying biological mechanisms, leading to better insights into disease etiology and  
294 potential therapeutic targets. We first used GWAS summary statistics to estimate the shared heritability ( $r_g$ )  
295 among NDDs and NPDs, revealing disease pairs (i.e., SCZ-BD, DLBD-PD) with a high degree of heritability  
296 overlap (**Fig. 5d**). This analysis differentiates between NDDs and NPDs, revealing lower shared heritability  
297 between NDDs and NPDs. We then quantified the pairwise transcriptome similarity ( $\rho_s$ ) across NDDs and  
298 NPDs (**Fig. 5e**). Our findings revealed varying degrees of transcriptomic overlap, with some exhibiting high  
299 similarity, particularly in disease pairs such as AD and DLBD. We calculated the pair-wise trait heritability-  
300 transcriptome concordance ( $r_g-\rho_s$ ) by comparing the shared heritability against the average transcriptome  
301 similarity across cell types. We observed a positive correlation between genetic and transcriptomic similarities  
302 (Spearman's  $\rho=0.56$ ), indicating that diseases with higher shared genetic risk also tend to have more similar  
303 gene expression profiles (**Fig. 5f**). We extended the  $r_g-\rho_s$  comparison by considering the transcriptional  
304 concordance for each cell type (**Fig. 5g, Supplementary Fig. 5d**). Among all cell types, the transcriptional  
305 concordance of Chandelier cells (IN\_PVALB\_CHC) had the highest similarity with the pairwise trait heritability.  
306 In summary, our approach allowed us to dissect disease signatures into shared and distinct components,  
307 revealing significant overlap in gene expression and genetic risk across NDDs and NPDs. These findings  
308 bolster our understanding of common and unique disease mechanisms, paving the way for novel therapeutic  
309 strategies targeting shared or distinct pathways.

310



311 **Fig. 5. Cross-disorder variation of gene expression.** (a) Pathways implicated by shared gene expression  
 312 changes across 8 disorders. Hypergeometric test with FDR  $\leq 0.01$  shown. (b) Transcriptome similarities  
 313 between disease pairs. Correlation is measured using Spearman correlation. Cross-disease shared genes are  
 314 discounted from the comparison. (c) Pathways implicated by shared signatures from AD, DLBD, Vas, and PD.  
 315 Hypergeometric test with FDR  $\leq 0.001$  shown. (d) Shared heritability estimates for disease pairs. LD Score  
 316 Regression (LDSC). (e) Transcriptome similarity measured by Spearman correlation. (f) Correlation between  
 317 shared heritability and median of transcriptome similarity. (g) Correlation between shared heritability and  
 318 transcriptome similarity per cell subclass.

## 320 Transcriptomic variation with AD pathology

321 Next, we focused on characterizing the transcriptomic variation in AD using case-control comparison, and  
 322 analysis of different phenotypes that capture disease severity, including plaque density using CERAD scores,  
 323 neurofibrillary tangle progression using Braak stage, and level of cognitive impairment. The analysis of  
 324 variation in cell type composition reveals distinct patterns associated with AD pathology compared to normal  
 325 aging (Fig. 6a, Supplementary Fig. 6a, Supplementary Table 5). Notably, changes unique to AD pathology,  
 326 such as the observed increase in Micro and IN\_LAMP5\_LHX6 with higher CERAD scores, indicate a potential  
 327 association between this neuronal subtype and A $\beta$  pathology. Additionally, the loss of EN\_L2\_3\_IT in AD  
 328 (based on case-control and CERAD comparisons), which is not evident in normal aging, suggests a specific  
 329 vulnerability for this neuronal subtype to AD. Placing subclasses based on compositional shifts of normal aging




330 and AD (**Fig. 6b**), we identified one of the vascular cell types, SMC, was having the opposite effect, suggesting  
331 an AD-specific vulnerability in SMC. Likewise, changes in most ENs were discordant suggesting the  
332 mechanisms that lead to neuronal loss are AD-specific. Taken together, our findings highlight the cell type-  
333 specificity of vulnerability associated with AD.

334 To better understand transcriptomic variation under AD pathology and to identify subclass most affected,  
335 we also analyzed the changes in AD cases due to co-occurring conditions. It is estimated that more than 80%  
336 of AD patients will exhibit at least one NPS over the course of their illness that significantly impacts their clinical  
337 outcomes<sup>5,55</sup> which suggests at least some shared molecular mechanisms between serious mental illness and  
338 AD. To evaluate cell type associations with the prevalence of NPS, we applied compositional variation analysis  
339 to three categories of NPS based on co-occurrence estimates. Notably, using age-matched groups of AD  
340 patients with or without NPS (**Supplementary Fig. 6b**), we found AD patients experiencing weight loss and  
341 PMA have an increased ratio of EN cell types, especially in deep layer neurons in L6 (**Fig. 6a, Supplementary**  
342 **Fig. 6a**). Our results support previous findings<sup>56</sup> that the deeper PFC layers (L5-6) are involved with certain  
343 types of NPS.

344 Upon identification of vulnerable cell subclasses in AD, we questioned their roles in AD pathology whether  
345 their changes are damaging, protective, causal, or derived. As demonstrated in previous studies<sup>57</sup>, we  
346 employed mediation analysis to decipher the causal relationships between various cascades of events leading  
347 to disease onset and progression of AD pathology. We performed the analysis on the base hypothesis that  
348 polygenic risk (AD PRS; **Methods**) contributes to plaque accumulation (mean density of neuritic plaques),  
349 which in turn affects tau progression (Braak), leading to varying degrees of dementia. We tested 14 subclasses  
350 that were significantly altered in any of the contrasts and observed significant average causal mediation effects  
351 (ACME,  $P < 0.05$ ) involving Microglia, VLNC, IN\_SST, and IN\_LAMP5\_LHX6 (**Fig. 6c**). Initially, we showed  
352 PRS affects both plaque and tau pathology, but tau is also significantly affected by plaque accumulation  
353 (ACME = 0.0903,  $P < 2e-16$ ). Then, tau progression results in more VLNC cells mediated by an increase in  
354 Microglia (ACME = 0.00477,  $P = 0.005$ ). Conversely, an increase in microglia leads to a decrease  
355 IN\_LAMP5\_LHX6. Such changes in the levels of both VLNC (ACME = 0.00515,  $P = 0.0002$ ) and  
356 IN\_LAMP5\_LHX6 (ACME = -0.00269,  $P = 0.031$ ) appear to exacerbate dementia. Furthermore, plaque  
357 accumulation is mitigated by IN\_SST cells (ACME = 0.1475,  $P < 2e-16$ ). Increased microglia lowers IN\_SST  
358 (coef = -0.18,  $P = 5.04e-07$ ), as does increased tau (coef = -0.06,  $P = 1.82e-04$ ), contributing to more plaque  
359 accumulation (coef = -2.01,  $P = 7.47e-06$ ).

360 To determine how gene programs change in response to increasing severity of AD pathology, we  
361 characterized the DEGs in 27 subclasses (**Fig. 6d, Supplementary Fig. 6d, Supplementary Table 6**). DEGs  
362 in general have high concordance across different AD pathology variables, consistent with previous reports<sup>1</sup>.  
363 Overall, DEGs in AD ( $FDR < 0.05$ ) can be summarized as up-regulation of genes in vascular cell classes  
364 (Mural and Endo) while down-regulation of genes in neurons (**Supplementary Fig. 6c**). We discovered genes  
365 differentially expressed in microglia were not observed in other subclasses, and these genes generally  
366 exhibited higher effect sizes. These include previously characterized up-regulated genes in Microglia, including  
367 DPYD, IL15, and PTPRG<sup>53,58,59</sup>. Further characterizing microglia-associated gene signatures, we found they  
368 are specifically enriched with pathways involved in negative regulation of cell motility and migration as well as  
369 response to lipoprotein particle (**Fig. 6e, Supplementary Fig. 6e**). Gene expression changes in neurons were  
370 largely affecting synaptic functions including synapse assembly, development, signaling, and membrane  
371 transport. Lastly, genes affecting VLNCs were implicated in muscle tissue development.

372





374 **Fig. 6. Transcriptome changes across AD neuropathology.** (a) Compositional variation analysis using  
375 normal aging, different measures of AD pathology (binary AD diagnosis (dx\_AD), CERAD score, Braak  
376 staging, and ordinal dementia scale), and 3 categories of NPS within AD. (b) Comparison of compositional  
377 changes between aging and AD. Green indicates changes are concordant. Red indicates changes are  
378 discordant. Only subclasses with at least one FDR significant contrast shown. (c) Causal mediation analysis  
379 using PRS, mean plaque, Braak staging, and dementia scale. CLR-transformed subclass fractions were used  
380 for modeling. Statistical significances are shown above the arrow ( $P < 0.001$  \*\*\*,  $< 0.01$  \*\*, and  $< 0.05$  \*), and  
381 numbers below indicate coefficients. Mediation effects of SST interneurons on A $\beta$  plaque accumulation shown  
382 separately. (d) DEGs in AD phenotypes. Meta-analysis between brain banks. Top genes with FDR  $< 0.01$  and  
383 effect size  $\geq 0.35$ . (e) Functional enrichment analysis of DEGs by subclass using Gene Ontology Biological  
384 Process. Hypergeometric test with FDR  $\leq 0.01$  shown. GO terms were reduced using rrvgo.

## 385 **Nonlinear dynamics of the AD pathological trajectory**

386 To understand AD dementia mediated by tau proteinopathy, we modeled the transcriptome using  
387 variational autoencoder (VAE)-based latent manifold mapping (**Fig. 7a, Methods**). We inferred two  
388 independent cell-type-specific disease trajectories from semi-quantitative measures of AD progression (tau  
389 proteinopathy and severity of cognitive decline) and explored the dynamics of two paths leading to the onset  
390 and early stage of AD pathogenesis. To decorrelate Braak and dementia model predictions, we equally  
391 sampled all combinations of Braak stage and dementia status during model training (**Supplementary Fig. 7**).  
392 The accuracy of the Braak and dementia model predictions were significantly above chance for all eight cell  
393 classes ( $P < 1e-4$ , bootstrap) (**Fig. 7b, top**). We built a disease trajectory using the predicted Braak staging as  
394 a pseudo-temporal axis (**Supplementary Figs. 8a,b**) and calculated a dementia resilience score that  
395 measured how gene expression is correlated with predicted dementia, conditioned on the predicted Braak  
396 staging (**Methods**). Specifically, a gene is considered protective (i.e., resilient against dementia), if increased  
397 expression is associated with a decrease in predicted dementia, and vice versa (damaging if increased  
398 expression is associated with an increase in predicted dementia). Many past studies have suggested that gene  
399 expression can evolve nonlinearly with disease progression<sup>60</sup>. Thus, we measured the degree of nonlinearity  
400 for each gene trajectory (**Supplementary Fig. 8c**) and revealed that those within the immune and neuronal cell  
401 class were the most nonlinear and linear, respectively (both  $P$ s  $< 1e-4$ , bootstrap) (**Fig. 7b, bottom**).

402 To further characterize the nonlinear evolution of gene expression, we defined an "early" and "late" disease  
403 stage (**Supplementary Fig. 8c**) and determined the top 32 GO BP pathways that best summarize the  
404 biological changes associated with early and late stages of tau proteinopathy and dementia resilience (**Fig. 7c,**  
405 **Supplementary Figs. 9-11, Supplementary Table 7**). A semantic clustering of the pathways identified five  
406 functional clusters. The first cluster was primarily related to synaptic function, which were characterized by  
407 down-regulation in OPCs in the early stages of AD, and then up-regulation in neurons in later stages. For both  
408 cell types, increased expression was associated with diminished resilience (i.e., damaging). The late increase  
409 of genes implicated in these pathways could be linked to compensatory mechanisms following synaptic loss<sup>61</sup>.  
410 The second cluster was related to cell metabolism pathways implicated in protein translation<sup>2,62</sup>, mitochondrial  
411 function<sup>2,63</sup>, and acidification<sup>64</sup>, which showed strong downregulation in neurons with increasing Braak,  
412 consistent with past studies<sup>65</sup>. Decreased expression in these metabolic pathways implied damaging  
413 association with decreased resilience (increase in metabolism was protective). The third cluster was related to  
414 cell stress, including pathways related to chaperone-mediated protein assembly, folding, and tau-kinase  
415 activity. In non-neuronal cells, increased cell stress was strongly associated with cognitive decline in both the  
416 early and late stages. The fourth cluster was related to immune response and inflammation. In immune cells,  
417 early increase in pathways such as microglial activation, phagocytosis, and B cell proliferation was observed,  
418 while late increase was involved with pathways implicated in adaptive immune responses such as antigen

419 presentation and T-cell response, all of which were associated with dementia resilience. Lastly, vascular cells  
420 were implicated in damaging changes such as reduced lipid transport and vascular permeability, response to  
421 interleukin-17 (IL-17), glycolysis, endothelial cell differentiation, and nitric oxide synthesis.

422 As previous studies have highlighted the importance of the immune response in AD<sup>58,66–72</sup>, we examined  
423 this cell class in more detail (**Figs. 7d-g**); We also extended the analysis to EN, IN and OPC cells classes  
424 (**Supplementary Figs. 12-15**). To help visualize the non-linear dynamics of the immune response to AD, we  
425 categorized gene expression trajectories into four modules based on their response to increasing tau  
426 proteinopathy: early increasing, early decreasing, late increasing, and late decreasing (**Fig. 7d**). Gene  
427 enrichment of these four trajectory modules showed that pathways involved in macrophage colony stimulation  
428 and metal transport were all upregulated in the early stage (**Fig. 7e**), whereas migration, purinergic signaling,  
429 and negative regulation of inclusion body assembly were downregulated. In the later stage, lipid-related  
430 pathways such as adipose tissue development, and triglyceride metabolism increased, while synapse-related  
431 pathways were downregulated. Gene-set enrichment analysis using GWAS summary statistics for the top 250  
432 genes in each trajectory module revealed that late increasing genes were the most strongly associated with AD  
433 (FDR  $\leq 4.1e-6$ ), although the other three modules were also significantly associated (FDR early increase  $\leq$   
434 0.005, early decrease  $\leq 0.048$ , late decrease  $\leq 0.040$  (**Fig. 7f, Supplementary Table 8, Supplementary Fig.**  
435 **12b**). Interestingly, the late increasing trajectory module was also significantly correlated with other NDDs,  
436 including MS and PD. We further examined the genes associated with trajectory modules (**Fig. 7g**, list of top  
437 genes for all cell classes are found in **Supplementary Table 9**). Markers for homeostatic microglia<sup>73</sup>, such as  
438 CX3CR1, NAV2 and P2RY12 were among the top 10 early decreasing genes with increasing proteinopathy  
439 (FRMD4A ranked 26th out 17,265 coding genes, **Supplementary Table 9**). Conversely, some of the early  
440 increasing genes, such as ACSL1, DPYD, and CD163 were recently implicated in a pathogenic lipid-droplet  
441 accumulation phenotype in individuals with AD who carry the APOE4/4 genotype (another implicated gene,  
442 NAMPT, ranked 54th. **Supplementary Table 9**)<sup>70</sup>. These genes, along with the later upregulation in lipid-  
443 related pathways such as adipose tissue development and triglyceride metabolism, lend support to the  
444 hypothesis that microglia develop a lipid-droplet accumulating state that potentially exacerbates disease  
445 progression<sup>70–72</sup>.

446



448 **Fig. 7. Modeling of AD using disease trajectory analysis. (a)** Overview of the trajectory inference model. **(b)**  
449 Accuracy of the model (above) and nonlinearity index by class (below). **(c)** Pathway enrichment by early (upper  
450 left triangles) and late (lower right triangles) phases of the AD trajectory, as predicted by Braak and dementia  
451 resilience. A gene is considered protective if increased expression is associated with a decrease in predicted  
452 dementia, and vice versa. Hue indicates the z-score (clipped between -10 and 10), and stars indicate  $FDR <$   
453  $0.05$ . **(d)** Four representative disease trajectory modules for immune cell class. The mean normalized  
454 expression of the 250 genes with greatest early increasing (blue curve), early decreasing (orange), late  
455 increasing (green) and late decreasing (red) slopes based on Braak trajectories. **(e)** Pathway enrichment of  
456 disease trajectory modules. Text colored by the four trajectory modules. Hue indicates the number of genes in  
457 the pathway. **(f)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color  
458 indicates neurological traits (red) and psychiatric traits (blue). Hue indicates  $-\log_{10}(FDR)$  (clipped at  
459 5), asterisk indicates  $FDR < 0.05$ . **(g)** Top 12 genes for each trajectory module. Hue indicates the rate of  
460 normalized expression change (slope) based on the predicted Braak staging. For visualization, we only show  
461 each gene once even if it appears in more than one module.

## 462 Discussion

463 We report a comprehensive disease atlas of the human DLPFC using 1,494 donors affected with various  
464 complex neurological and psychiatric conditions. Our single-nucleus transcriptomic analyses provide novel  
465 insights about cellular heterogeneity and variability in the human brain, including the observation that about  
466 10% of total transcriptomic variation can be attributed to inter-individual differences. Intriguingly, we find genes  
467 with higher inter-individual variability and lower genetic constraints that were implicated in certain  
468 housekeeping roles<sup>51</sup>. This is in contrast to the idea that, due to their essential nature, housekeeping genes are  
469 more likely to be conserved<sup>74,75</sup>. They are among the most universal genes in the cell, and cells adapt their  
470 protein synthesis machinery in response to physiological needs<sup>76</sup>. This flexibility is crucial for processes such  
471 as differentiation, proliferation, and response to stress. A higher degree of regulatory flexibility suggests a  
472 tolerance for variation within certain constraints.

473 We used the disease atlas to characterize cellular and disease-specific responses to pathologic conditions.  
474 Our findings reveal shared and distinct cellular composition profiles among NDDs and NPDs, furthering our  
475 understanding of their underlying pathophysiological mechanisms. Disease signatures shared across NDDs  
476 and NPDs are enriched with genes critical for the proper functioning of cellular processes, such as RNA  
477 splicing. This observation aligns with the omnigenic model<sup>54</sup>, where most heritability in complex traits can be  
478 explained by effects on peripheral genes that often play indirect, subtle, and cumulative roles in disease. Thus,  
479 discounting cross-disease effects could facilitate identification of core disease-relevant functional genes. Using  
480 this approach, we found that disease pairs with higher genetic risk overlap tend to have greater transcriptomic  
481 concordance, in a cell-type-dependent manner, suggesting that genetic factors contributing to disease  
482 susceptibility can also influence transcriptomic alterations in similar ways<sup>3</sup>.

483 In addition, we revealed that the brain vascular system is intricately linked to immune dysfunction in NDDs.  
484 In general, we saw a relative increase in vascular cell types in most NDDs and demonstrate that, in a  
485 seemingly protective role, levels of VLMCs rise in individuals who experience exacerbated cognitive  
486 impairment in AD. It has previously been shown that the meningeal lymphatic system plays multiple roles in the  
487 brain, including waste removal<sup>77-79</sup> and the adaptive immune response<sup>52,80</sup>. Given the role of VLMCs in these  
488 processes<sup>81-84</sup>, they warrant further investigation in the context of NDDs.

489 Our analysis of the pathological trajectory of AD aligns with various proposed hypotheses<sup>65,85-89</sup>,  
490 particularly for pathways affected in the earliest stages of the disease. Neuronal, immune, and vascular cells  
491 exhibit distinct vulnerabilities, with shared alterations across correlated pathways. In neurons, we observed a  
492 decrease in metabolic functions (cyclic nucleotide catabolic process, cytoplasmic translation, and ATP



493 synthesis) that have been closely linked to synaptic dysfunction and cognitive decline<sup>65</sup>. The immune response  
494 was generally protective against cognitive decline: an early innate immune activation<sup>85</sup> followed by an adaptive  
495 immune response<sup>67–69</sup> was associated with dementia resilience. The one exception was the response to IL-17,  
496 which was damaging in the early stages of AD for the Immune, Mural, and Endo classes. IL-17 has been  
497 associated with cognitive decline<sup>90,91</sup> and disruption of the blood-brain barrier<sup>92</sup>, with anti-IL-17 treatment  
498 restoring cognitive function in mice<sup>90,91</sup>. In addition, chaperones have been closely associated with a number of  
499 disease related processes, including tau misfolding and aggregation, and neurotoxicity<sup>86–89,93,94</sup>, however, their  
500 precise roles in AD pathogenesis remains unclear. Our results suggest that chaperones can play opposing  
501 roles; protective for neurons but damaging for glia and immune cells. Lastly, vascular cells are associated with  
502 negative regulation of vascular permeability and lipid transport, which are detrimental to the infiltration of  
503 perivascular immune cells<sup>95</sup> and the clearance of protein aggregates. Taken together, these insights deepen  
504 our understanding of AD pathogenesis and implicate cellular responses that warrant further investigation.  
505 Overall, the PsychAD single-cell disease atlas serves as a unique and foundational resource to further our  
506 understanding of population-level disease-associated transcriptomic variation in the human brain.

## 507 **Methods**

### 508 **Collection and harmonization of clinical, pathological, and demographic metadata**

509 Brain tissue specimens were sourced from two brain banks: the Mount Sinai NIH Neurobiobank (MSSM;  
510 1,042 samples) and the NIMH-IRP Human Brain Collection Core (HBCC; 300 samples). Additionally, samples  
511 were obtained from five prospective cohort studies conducted at the Rush Alzheimer's Disease Center (RADCC;  
512 152 samples)<sup>96,97</sup>. As such, the available clinical data varied as a function of source (**Supplementary Fig. 4a**).  
513 We used the following scheme to harmonize available clinical, pathological, and demographic metadata: the  
514 CERAD scoring scheme for neuritic plaque density<sup>98</sup> was harmonized for consistency across multiple brain  
515 banks, where the scores range from 1 to 4, with increasing CERAD number corresponding to an increase in  
516 AD burden; 1=no neuritic plaque (normal brain), 2=sparse (possible AD), 3=moderate (probable AD),  
517 4=frequent (definite AD). Samples from RADCC used consensus summary diagnosis of no cognitive impairment  
518 (NCI), mild cognitive impairment (MCI), and dementia and its principal cause, Alzheimer's dementia<sup>99–101</sup>.  
519 MSSM samples used clinical dementia rating (CDR), which was based on a scale of 0-5; 0=no dementia,  
520 0.5=questionable dementia (very mild), 1=mild dementia, 2=moderate dementia, 3=severe dementia,  
521 4=profound dementia, 5=terminal dementia. After consulting with clinicians, we created a harmonized ordinal  
522 variable where dementia is categorized into three levels of cognitive decline, independent of AD diagnosis;  
523 0=no cognitive impairment, 0.5=MCI (mild cognitive impairment), and 1-5=dementia. In addition to AD  
524 phenotype, we collected comprehensive demographic (age, sex, and genetic ancestry) and technical variables  
525 (tissue source, technician, sample batch, postmortem interval (PMI; measured in minutes), ApoE genotype) to  
526 describe each cohort (**Supplementary Table 1**). We briefly describe the process for assigning genetic  
527 ancestry<sup>102</sup>. In particular, we leveraged quadratic discriminant analysis (QDA) to infer genetic ancestry by  
528 training our model using data from the 1000 Genomes Project. We utilized 10-fold stratified cross validation to  
529 optimize the regularization parameter within QDA<sup>103</sup> as well as forward selection to identify the optimal number  
530 of principal components for genetic ancestry assignments. For samples without genotypic data we utilized  
531 race/ethnicity as a proxy for inferring genetic ancestry. We emphasize that while genetic ancestry is a distinct  
532 concept from the social constructs of race and ethnicity<sup>104</sup>, we leveraged the correlated race/ethnicity variables  
533 as proxies to retain those samples in the analyses. Values for superpopulations included: EAS, SAS, AFR,  
534 AMR, EUR, and EAS\_SAS, where the category "EAS\_SAS" was assigned for samples with unavailable  
535 genotypes with an "Asian" value for race/ethnicity, which can potentially correspond to both EAS and SAS.  
536

## 537 **Clinical diagnosis of AD**

538 For analysis comparing donors with AD cases and neurotypical controls, a binary clinical diagnosis variable  
539 for AD, *dx\_AD*, was defined, as follows: Individuals with CERAD 2, 3, or 4, Braak  $\geq 3$ , and CDR  $\geq 1$  for MSSM  
540 or Alzheimer's dementia for RADC were classified as AD cases. Controls were defined as individuals in  
541 *controls\_neuropathological\_clinical* category where CERAD={1}, Braak={0,1,2,3}, and secondary diagnosis  
542 (including dementia) is not allowed except for MCI.

543

## 544 **Measuring AD neuropathology**

545 For analysis comparing donors with pathologic AD, the following variables were used to measure the  
546 severity of AD neuropathology: **CERAD score**<sup>98</sup>. A quantitative measure of A $\beta$  plaque density where 1 is  
547 normal, 2 is possible AD, 3 is probable AD, and 4 is definite AD<sup>99</sup>. **Braak AD-staging score** measuring  
548 progression of neurofibrillary tangle neuropathology (Braak & Braak-score, or BBScore). A quantitative  
549 measure of the regional patterns of neurofibrillary tangle (NFT) density across the brain, where 0 is normal and  
550 asymptomatic, 1-2 indicate initial stages where NFT begins to appear in the locus coeruleus and the  
551 transentorhinal region, 3-4 indicate progression to limbic regions, such as the hippocampus and amygdala, and  
552 5-6 indicate NFT are widespread, affecting multiple cortical regions<sup>105-107</sup>.

553

## 554 **Measuring cognitive impairment**

555 For analysis comparing donors with AD-related dementia, the following variable was used to measure the  
556 severity of cognitive impairment: **Clinical assessment of dementia**. A harmonized variable of cognitive status  
557 based on the CDR scale for MSSM or NCI, MCI, and Alzheimer's dementia for RADC. We used the three-level  
558 ordinal categories of clinical dementia to measure the severity of dementia, in which 0 indicates no dementia,  
559 0.5 indicates minor cognitive impairment, and 1.0 indicates definite clinical dementia.

560

## 561 **Definition of cross-disorder contrasts**

562 For cross-disorder contrasts, we limited the analysis to any individual with Age  $\geq 17$ . Neurotypical controls  
563 are defined as any individual CERAD={1}, Braak={0,1,2,3}, and secondary diagnosis is not allowed. AD is any  
564 individual with CERAD={2,3,4}, Braak={3,4,5,6}, clinically diagnosed as dementia, and secondary diagnosis  
565 not allowed. SCZ is any individual with SCZ diagnosis (*SCZ* | *Schizoaffective\_bipolar* |  
566 *Schizoaffective\_depressive*) and secondary diagnosis not allowed, except for metabolic and eating disorders.  
567 DLBD is any individual with DLBD diagnosis (*DLBD*) and secondary diagnosis can be only AD. Vascular is any  
568 individual with Vascular diagnosis (*Vascular*) and secondary diagnosis can be only AD. BD is any individual  
569 with BD diagnosis (*BD\_unspecific* | *BD\_I* | *BD\_II* | *Schizoaffective\_bipolar*) and secondary diagnosis not  
570 allowed except for metabolic and eating disorders. Tauopathy is any individual with CERAD={1}, Braak={4,5,6}  
571 and secondary diagnosis allowed. PD is any individual with PD diagnosis (*PD* |  
572 *PD\_uncertain\_plus\_encephalitic*) and secondary diagnosis can be only AD. FTD is any individual with FTD  
573 diagnosis (*FTD*) and secondary diagnosis can be only AD. All disease contrasts used in the study can be  
574 found in **Supplementary Table 1**.

575

## 576 **Isolation and fluorescence-activated nuclear sorting (FANS) of nuclei from frozen brain specimens with hashing**

578 All buffers were supplemented with RNase inhibitors (Takara). 25mg of frozen postmortem human brain  
579 tissue was homogenized in cold lysis buffer (0.32M Sucrose, 5 mM CaCl<sub>2</sub>, 3 mM Magnesium acetate, 0.1 mM,  
580 EDTA, 10 mM Tris-HCl, pH8, 1 mM DTT, 0.1% Triton X-100) and filtered through a 40  $\mu$ m cell strainer. The  
581 flow-through was underlaid with sucrose solution (1.8 M Sucrose, 3 mM Magnesium acetate, 1 mM DTT, 10  
582 mM Tris-HCl, pH8) and centrifuged at 107,000 xg for 1 hour at 4°C. Pellets were resuspended in PBS



583 supplemented with 0.5% bovine serum albumin (BSA). 6 samples were processed in parallel. Up to 2M nuclei  
584 from each sample were pelleted at 500 xg for 5 minutes at 4°C. Nuclei were re-suspended in 100 µl staining  
585 buffer (2% BSA, 0.02% Tween-20 in PBS) and incubated with 1 µg of a unique TotalSeq-A nuclear hashing  
586 antibody (Biolegend) for 30 min at 4°C. Prior to FANS, volumes were brought up to 250 µl with PBS and 7-  
587 Aminoactinomycin D (7-AAD) (Invitrogen) added according to the manufacturer's instructions. 7-AAD positive  
588 nuclei were sorted into tubes pre-coated with 5% BSA using a FACSAria flow cytometer (BD Biosciences).  
589

### 590 **snRNA-seq and hashing library preparation**

591 Following FANS, nuclei were subjected to 2 washes in 200 µl staining buffer, after which they were re-  
592 suspended in 15 µl PBS and quantified (Countess II, Life Technologies). Concentrations were normalized and  
593 equal amounts of differentially hash-tagged nuclei were pooled. Using 10x Genomics single cell 3' v3.1  
594 reagents (10x Genomics), 60,000 (10,000 per donor) nuclei were run in each of x2 10x Genomics lanes to  
595 create a technical replicate. At the cDNA amplification step (step 2.2) during library preparation, 1 µl of 2 µm  
596 HTO cDNA PCR "additive" primer was added<sup>108</sup>. After cDNA amplification, supernatant from 0.6x SPRI  
597 selection was retained for HTO library generation. cDNA libraries were prepared according to the 10x  
598 Genomics protocol. HTO libraries were prepared as previously described<sup>108</sup>. cDNA and HTO libraries were  
599 sequenced at NYGC using the Novaseq platform (Illumina).  
600

### 601 **Processing of snRNA-seq data**

602 **Alignment.** Paired-end snRNA-seq library reads were aligned to the hg38 reference genome using STAR  
603 solo<sup>109,110</sup> and sample pools were demultiplexed using genotype matching via vireoSNP<sup>111</sup>. After per-library  
604 count matrices were generated, the downstream processing was performed using Pegasus v1.7.0<sup>112</sup> and  
605 scanpy v1.9.1<sup>113</sup>. **QC.** We applied rigorous three-step QC to remove ambient RNA and retain high quality  
606 nuclei for subsequent downstream analysis. First, QC was applied at the cell level. Poor-quality nuclei were  
607 detected by thresholding based on UMI counts, gene counts, and mitochondrial content. We also checked for  
608 possible contamination from ambient RNA, fraction of reads mapped to non-mRNAs, like rRNA, sRNA, and  
609 pseudogenes, as well as known confounding features such as lncRNA MALAT1. Second, QC was applied at  
610 the feature level by removing features that were not robustly expressed by at least 0.05% of the nuclei. Lastly,  
611 QC was applied at the donor level by removing donors with very low nuclei counts, which can introduce noise  
612 to downstream analyses. We also removed donors with low genotype concordance. Further filtering was  
613 carried out by removing doublets using the Scrublet method<sup>114</sup>. **Batch correction.** We assessed the  
614 correlation between all pairs of technical variables using Canonical Correlation Analysis and used the Harmony  
615 method<sup>115</sup> to regress out unwanted variables such as the effect of brain tissue source.  
616

### 617 **Defining cellular taxonomy using iterative clustering**

618 Cellular taxonomy was defined using a divide-and-conquer strategy. From the full dataset containing over 6  
619 million nuclei, 8 major cell classes were defined using the following steps. We selected 6,000 highly variable  
620 genes (HVGs) from mean and dispersions trends<sup>116</sup> using the default parameters (min\_mean=0.0125,  
621 max\_mean=3, min\_disp=0.5) and brain sources as batch variable after manually excluding sex and  
622 mitochondrial chromosomes and MT. We used the k-nearest-neighbor (kNN) graph calculated on the basis of  
623 harmony-corrected PCA embedding space to cluster nuclei of the same cell type using Leiden<sup>117</sup> clustering  
624 algorithms. We used UMAP<sup>118</sup> to visualize the resulting clusters. From the class-level clusters, we subsetted  
625 the data by each class. Re-calculating HVGs among cells in the same class allowed us to re-focus on a feature  
626 space that is more relevant for the same class of cells. We then calculated kNN graph on the basis of the  
627 harmony-corrected PCA of the selected HVGs. Leiden-clustering was used to annotate subclass-level  
628 annotations. We iterated to the second level of taxonomy yielding 67 subtypes of human brain cells.  
629

## 630 **Spatial validation of cellular taxonomy**

631 **Xenium *in situ* panel selection and custom panel design.** Xenium Human Brain Gene Expression Panel  
632 (1000599, 10x Genomics) and a custom panel of 100 genes (**Supplementary Table 10**) were selected for the  
633 Xenium experiment. The 100 gene custom panel consisted mainly of subclass markers selected based on  
634 specificity and gene expression level. The custom gene list was sent to 10X genomics and the probe design  
635 was performed using their in-house pipeline.

636 **Tissue preparation.** Fresh frozen tissue specimens of DLPFC were dissected into small blocks on ice. Tissue  
637 blocks were snap frozen by submerging in an isopentane (320404-1L, Sigma-Aldrich) bath chilled with dry ice  
638 and stored in -80 °C. Before cryosectioning, tissue blocks were allowed to equilibrate to the cryostat (HM505,  
639 Microm) chamber temperature, and were mounted with OCT (Tissue-Tek® O.C.T. Compound, 4583, Sakura  
640 Finetek USA). After trimming, good quality 10 µm sections were flattened on the cryostat stage and placed on  
641 pre-equilibrated Xenium slides (Xenium Slides & Sample Prep Reagents, 1000460, 10x Genomics). 2-3  
642 sections were placed on each slide. Sections were further adhered by placing a finger on the backside of the  
643 slide for a few seconds and were then refrozen in the cryostat chamber. Slides were sealed in 50 ml tubes and  
644 stored at -80 °C until Xenium sample preparation.

645 **Sample preparation.** Xenium sample preparation was performed according to the manufacturer's protocol;  
646 "*Xenium In Situ for Fresh Frozen Tissues – Fixation & Permeabilization, CG000581, Rev C*" and "*Xenium In*  
647 *Situ Gene Expression - Probe Hybridization, Ligation & Amplification, User Guide, CG000582, Rev C*". Briefly,  
648 fresh frozen sections mounted on Xenium slides from the previous step were removed from -80 °C storage on  
649 dry ice prior to incubation at 37 °C for 1 min. Samples were then fixed in 4% paraformaldehyde (Formaldehyde  
650 16% in aqueous solution, 100503-917, VWR) in PBS for 30 min. After rinsing in PBS, the samples were  
651 permeabilized in 1% SDS (sodium dodecyl sulfate solution) for 2 min, and then rinsed in PBS before being  
652 immersed in the pre-chilled 70% methanol and incubated for 60 min on ice. After rinsing the samples in PBS,  
653 the Xenium Cassettes were assembled on the slides. Samples were incubated with a probe hybridization mix  
654 containing both the Xenium Human Brain Gene Expression Panel (1000599, 10x Genomics) and a 100 custom  
655 gene panel at 50°C overnight to allow the probes to hybridize to targeted mRNAs. After probe hybridization,  
656 samples were rinsed with PBST, and incubated with Xenium Post Hybridization Wash Buffer at 37°C for 30  
657 min. Samples were then rinsed with PBST and ligation mix was added. Ligation was performed at 37°C for 2  
658 hrs to circularize the hybridized probes. After rinsing the samples with PBST, Amplification Master Mix was  
659 added to enzymatically amplify the circularized probes at 30 °C for 2 hrs. After washing with TE buffer, auto-  
660 fluorescence was quenched according to the manufacturer's protocol and nuclei stained with DAPI prior to  
661 Xenium *in situ* analysis.

662 **Data processing.** The prepared samples were loaded into the Xenium analyzer and run according to  
663 manufacturer's instructions "*Xenium Analyzer User Guide CG000584 Rev B*". After the Xenium analyzer was  
664 initiated, the correct gene panel was chosen, and decoding consumables (Xenium Decoding Consumables,  
665 PN-1000487, 10x Genomics) and reagents (Xenium Decoding Reagents, PN-1000461, 10x Genomics) were  
666 loaded. The bottom of the slides were carefully cleaned with ethanol prior to loading. Once the samples were  
667 loaded and the run was initiated, the instrument scanned the whole sample area of the slides using the DAPI  
668 channel, and regions of interest were selected to maximize the capture area. Results were generated by the  
669 instrument using default settings. By default, the Xenium analyzer uses 15 µm nuclei expansion distance for  
670 segmentation of cells. To test the idea of nuclei only segmentation, we resegment the results with 0 µm nuclei  
671 expansion, by using the Xenium ranger and the following scripts:

```
672 xeniumranger resegment --id=demo --xenium-bundle=/path/to/xenium/files --  
673 expansion-distance=0 --resegment-nuclei=True
```

674 **Major cell type identification.** After nuclei were segmented, cell x gene matrices were generated from the  
675 overlap of each segmented nuclear boundary with detected transcripts in the Xenium experiment. Nuclei were  
676 subsequently filtered by the number of detected transcripts, and only those containing at least 40 nuclear  
677 transcripts were retained for downstream analysis. Gene expression data from each sample was then log-  
678 normalized and normalized data were used for PCA, kNN graph calculation and Leiden clustering. Clusters  
679 were then assigned to one of 8 major cell types based on marker gene expression.

680  
681 **Label prediction from snRNA-seq data using scANVI.** As an alternative to marker-based annotation, we  
682 used scANVI<sup>119</sup> to perform reference-based label transfer from the RADC dataset. Briefly, we followed the  
683 following steps. First, snRNA-seq gene expression data was subset to the genes shared with the Xenium gene  
684 panel. Next, we used the scvi-tools package<sup>120,121</sup> to train machine learning models for dimensionality reduction  
685 based on the reference dataset and its assigned labels (e.g., class and subclass). Models were run with 5  
686 layers and 30 latent variables, and the scANVI model was trained for 20 epochs with a minimal sample of 100  
687 cells per cluster per epoch. Lastly, a transfer model was trained for 100 epochs and applied to query data to  
688 assign labels based on those the model was trained on from the reference. To assess the performance of each  
689 transfer model, we asked the model to predict labels in the reference data (using the subset gene pool) and  
690 evaluated the rate of correct prediction and biases in label misassignment for each predicted label.

691  
692 **Subclass label transfer for EN (IN) cells.** To assign subclass labels for EN and IN nuclei, nuclei from all  
693 samples were filtered to EN (IN) based on two alternative methods for major cell type prediction - that  
694 described above, and label transfer using scANVI (with the RADC dataset as a reference). After subsetting to  
695 nuclei labeled as EN (IN) by both methods, these were then used as a query for a second scANVI label  
696 transfer - this one trained on subclass labels. Accuracy for both major cell type and subclass models assessed  
697 by predicted labels in the RADC dataset based only on the Xenium gene panel was estimated at > 98%.

## 698 699 **Processing of genotypes**

700 DNA extraction and genotyping was performed as described previously<sup>122</sup>. In brief, genomic DNA was  
701 extracted from frozen brain tissue using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's  
702 instructions. Samples were genotyped using the Infinium Psych Chip Array (Illumina) at the Mount Sinai  
703 Sequencing Core. Pre-imputation processing consisted of running the quality control script HRC-1000G-check-  
704 bim.pl from the McCarthy Lab Group (<https://www.well.ox.ac.uk/~wrayner/tools/>), using the Trans-Omics for  
705 Precision Medicine (TOPMed)<sup>123</sup>. Genotypes were then phased and imputed on the TOPMed Imputation  
706 Server (<https://imputation.biodatacatalyst.nih.gov>). Samples with a mismatch between one's self-reported  
707 and genetically inferred sex, suspected sex chromosome aneuploidies, high relatedness as defined by the  
708 KING kinship coefficient<sup>124</sup> (KING > 0.177), and outlier heterozygosity (+/- 3SD from mean) were removed.  
709 Additionally, samples with a sample-level missingness > 0.05 were removed and calculated within a subset of  
710 high-quality variants (variant-level missingness ≤ 0.02).

711 For ancestry assignment, genotypes were first merged with GRCh38 v2a 1000 Genomes Project data  
712 (<https://wellcomeopenresearch.org/articles/4-50>)<sup>125</sup> using BCftools version 1.9<sup>126</sup>. PLINK 2.0<sup>127</sup> was then used  
713 to calculate the merged genotypes' principal components (PCs), following filtering (minor allele frequency  
714 (MAF) ≥ 0.01, Hardy-Weinberg equilibrium (HWE)  $P \geq 1 \times 10^{-10}$ , variant-level missingness ≤ 0.01, regions with  
715 high linkage disequilibrium (LD) removed) and LD pruning (window size = 1000 kb, step size = 10,  $r^2 = 0.2$ )  
716 steps. For the samples of EUR ancestry assigned using the QDA method, autosomal bi-allelic variants with an  
717 imputation  $R^2 > 0.8$ , HWE  $P \geq 1 \times 10^{-6}$ , and variant-level missingness ≤ 0.02 were retained. Genotypes were

718 then annotated with ancestry-specific MAF values from the National Center for Biotechnology Information's  
719 Allele Frequency Aggregator (ALFA) ([https://ftp.ncbi.nih.gov/snp/population\\_frequency/latest\\_release/](https://ftp.ncbi.nih.gov/snp/population_frequency/latest_release/)). Only  
720 variants with an ancestry-specific ALFA MAF  $\geq 0.01$  were retained.

721

## 722 Polygenic risk score calculation

723 Polygenic risk scores (PRS) were computed for the PsychAD cohort using summary statistics from AD  
724 GWAS<sup>11</sup>. The PRS-CS-auto method<sup>128</sup> was employed, which incorporates continuous shrinkage priors to  
725 adjust the effect sizes from these summary statistics. An LD reference panel from the developers of PRS-CS,  
726 based on data from the 1000 Genomes Project<sup>125</sup>, was used (<https://github.com/getian107/PRSs>). The  
727 default settings for PRS-CS were applied, including parameters  $a = 1$  and  $b = 0.5$  for the  $\gamma$ - $\gamma$  prior, 1000  
728 Markov Chain Monte Carlo (MCMC) iterations, 500 burn-in iterations, and a thinning factor of 5. The global  
729 shrinkage parameter  $\phi$  was determined using a fully Bayesian method. PLINK 2.0<sup>127</sup> was utilized to calculate  
730 the individual-level PRS.

731

## 732 Genetic heritability analysis of polygenic risk

733 We established a standardized pipeline for Multi-marker Analysis of GenoMic Annotation (MAGMA)  
734 followed by single-cell Disease-Relevance Scoring (scDRS). MAGMA incorporates the association P-values of  
735 genetic variants from the latest genome-wide association study (GWAS). We used the following GWAS  
736 summary stats in scDRS/MAGMA pipeline: AD<sup>11</sup>, MS<sup>12</sup>, PD<sup>13</sup>, Epilepsy<sup>14</sup>, Migraines<sup>15</sup>, Stroke<sup>16</sup>, ALS<sup>17</sup>, SCZ<sup>18</sup>,  
737 BD<sup>19</sup>, MDD<sup>20</sup>, ASD<sup>21</sup>, ADHD<sup>22</sup>, Insomnia<sup>23</sup>, Education<sup>24</sup>, IQ<sup>25</sup>, Alcoholism<sup>26</sup>, OCD<sup>27</sup>, Tourettes<sup>28</sup>, Obesity<sup>29</sup>,  
738 T2D<sup>30</sup>, Cholesterol<sup>31</sup>, RArthritis<sup>32</sup>, IBD<sup>33</sup>, UC<sup>34</sup>. We applied MAGMA using a standard window of 35 kbp  
739 upstream and 10 kbp downstream around the gene body. We executed scDRS using the top 1000 gene  
740 weights, sorted by Z score. The MAGMA and scDRS pipeline was run using the following parameters. MAGMA  
741 was run using `-snp-loc g1000_eur.bim` (SNP location file corresponding to the Phase 3 1000 Genome  
742 Project) and `--gene-loc NCBI38.gene.loc` (gene location file from NCBI build 38). Both files were  
743 obtained from <https://ctg.cncr.nl/software/magma>. For scDRS, default setting was applied.

744

## 745 Variance partition analysis of gene expression

746 After aggregating pseudobulk by library, assays (cell types) were stacked using the *StackedAssay* function  
747 of Dreamlet. The resulting pseudobulk allowed us to perform analysis across cell types. Variance partition  
748 analysis was performed on the resulting stacked pseudobulk. We used the following regression formula:

749

750 
$$\text{Gene expression} \sim (1|\text{stackedAssay}) + (1|\text{Channel}) + (1|\text{SubID}) + (1|\text{Source}) +$$
  
751 
$$(1|\text{Ethnicity}) + dx\_bit + \text{scale}(\text{Age}) + \text{Sex} + \text{scale}(\text{PMI}) + \log(n\_genes) +$$
  
752 
$$\text{percent\_mito} + \text{mito\_genes} + \text{ribo\_genes} + \text{mito\_ribo}$$

753

754 where *dx\_bit* indicates binary disease status excluding metabolic and eating disorders. Technical covariates  
755 *log(n\_genes)*, *percent\_mito*, *mito\_genes*, *ribo\_genes*, and *mito\_ribo* were removed from the plotting and  
756 subsequent analysis because they explained less than 1e-4 percent of overall gene expression variation.

757

## 758 MAPT locus haplotyping

759 From our harmonized genotype calls, we selected common variants in 17q21.31 locus (chr17:45307631-  
760 46836264), performed PCA analysis of genotypes using 10 PCs, and used K-means clustering with  $k=3$  to call  
761 three genotype clusters, H1H1, H1H2, and H2H2. We additionally confirmed the H1 haplotype using two  
762 published SNPs, rs17763050 and rs8070723, known to associate<sup>129</sup>. Haplotypes were estimated using Beagle  
763 v5.4<sup>130</sup> on the selected genotypes of the 17q21.31 region. The estimation of the initial haplotype frequency



764 model converged after one burn-in iteration, and the estimate of the genotype phase converged after 23  
765 phasing iterations. For testing association with PD diagnosis, we used logistic regression with age, sex, 10  
766 genotype PCs, and H1H1 status:

767  
768  $PD \sim \text{Age} + \text{Sex} + \text{Source} + PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + PC8 + PC9 +$   
769  $PC10 + H1H1$

770  
771 In addition, we tested the contribution of the H1 haplotype to AD among non-ApoE4 carriers<sup>49</sup> but did not find a  
772 significant association ( $P \leq 0.302$ ). For testing association with AD diagnosis, we first subsetted for individuals  
773 who are not carriers of the ApoE4 allele and tested for AD association using logistic regression with the  
774 formula:

775  
776  $AD \sim \text{Age} + \text{Sex} + \text{Source} + PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + PC8 + PC9 +$   
777  $PC10 + H1H1$

778

### 779 **Compositional variation analysis using Crumblr**

780 We applied the Crumblr method (<https://diseaseneurogenomics.github.io/crumblr>) for testing the variation  
781 of cell type composition<sup>131</sup>. In summary, Crumblr scales the cell count ratio (i.e., fractions) data using centered  
782 log-ratio (CLR) transformation and applies linear models. Since CLR-transformed data is still highly  
783 heteroskedastic, the precision of measurements varies widely. Crumblr uses a fast asymptotic normal  
784 approximation of CLR-transformed counts from a Dirichlet-multinomial distribution to model the sampling  
785 variance of the transformed counts. Crumblr enables incorporating the sampling variance as precision weights  
786 to linear (mixed) models in order to increase power and control the false positive rate. Crumblr also uses a  
787 variance stabilizing transform based on the precision weights to improve the performance of PCA and  
788 clustering. Hypothesis testing was computed using the following formula:

789  
790  $\text{Cell composition} \sim \text{scale}(\text{Age}) + \text{Sex} + (\text{phenotype of interest})$

791

792 By including these variables, we account for potential confounders and improve the accuracy and reliability of  
793 our hypothesis testing (**Supplementary Fig. 4b**).

794

### 795 **Differential gene expression analysis using Dreamlet**

796 Due to the increased variable complexity in a large-scale disease atlas, scaling single-cell based  
797 approaches to millions of cells across a wide range of phenotypes presents computational challenges<sup>132</sup> and  
798 can be suboptimal<sup>133–136</sup>. To account for the scale of these data, complex study designs with repeated  
799 measures, and low read count per cell, we applied Dreamlet for differential expression analysis, which applies  
800 a pseudobulk approach. Building from the previously developed statistical tool Dream<sup>137</sup>, it applies linear mixed  
801 models to the differential expression problem in single-cell omics data. It starts by aggregating cells by the  
802 donor using a pseudobulk approach<sup>133,134</sup> and fits a regression model and cell. For each feature and cell  
803 cluster, the following mixed model was applied:

804

805  $\text{Gene expression} \sim \text{scale}(\text{Age}) + \text{Sex} + \text{scale}(\text{PMI}) + \log(\text{n\_genes}) + \text{percent\_mito} +$   
806  $\text{mito\_genes} + \text{mito\_ribo} + \text{ribo\_genes} + (\text{phenotype of interest})$

807

808 where categorical and numerical variables were modeled as random and fixed effects, respectively. If the  
809 phenotype of interest was a categorical variable, we set the intercept as 0 and used pre-defined contrasts  
810 between two factors. We ran a gene set analysis using the full spectrum of gene-level t-statistics<sup>138</sup>.

811

### 812 **Meta-Analysis (between brain sources):**

813 We conducted a meta-analysis to integrate results from different brain banks for the same disorder. Data  
814 tables from multiple brain banks were combined into a single list for each disorder and annotated with their  
815 respective sources. The `meta_analysis` function was used to perform the meta-analysis, which involved  
816 combining data tables into a single data frame, grouping the data by assay, and calculating standard errors  
817 using the formula `abs(logFC / t)`. The meta-analysis was performed using the `rma` function from the  
818 `metafor` package with a fixed effects model. P-values were adjusted using the False Discovery Rate (FDR)  
819 method, and the negative log10 of the FDR values were calculated. This method was applied to datasets of  
820 AD, DLBD, Vas, PD, Tau, FTD, SCZ, and BD.

821

### 822 **Meta-Analysis (across the same disease category)**

823 To further synthesize findings across multiple disorders, a `meta-of-meta` analysis was conducted,  
824 grouping the disorders into neurodegenerative and neuropsychiatric categories. Results from the initial meta-  
825 analyses for each disorder were combined into lists based on their categories. The `meta-of-meta` function  
826 was used to perform this higher-level analysis. This function combined the meta-analysis results into a single  
827 data frame, grouped the data by assay, and calculated standard errors using the formula `abs(estimate /`  
828 `statistic)`. This approach was applied to create `meta-of-meta` analyses for all disorders,  
829 neurodegenerative disorders, and neuropsychiatric disorders.

830

### 831 **Evaluation of shared disease signatures using Mashr**

832 Suppose the total disease signature can be written as the sum of shared and distinct components of DEGs  
833 for that disease:

834

$$\Delta\tau_k = \sum_{i \in G_{\text{shared}}} \Delta\tau_{i,k} + \sum_{j \in G_{\text{distinct}}} \Delta\tau_{j,k}$$

835

836 where  $\Delta\tau_k$  denotes the total disease signature for a disease  $k$ ,  $G_{\text{shared}}$  denotes the set of DEGs that are  
837 shared among the diseases,  $G_{\text{distinct}}$  denotes the set of DEGs that are distinct for diseases. This notation  
838 highlights that the total differential gene expression for each disease is composed of contributions from both  
839 shared genes (common to all diseases) and distinct genes (specific to each disease). To define shared  
840 disease signatures, we performed composite tests on Dreamlet results using Mashr to evaluate the specificity  
841 of an effect. We evaluated the posterior probability of a non-zero effect present in all 8 cross-disorder  
842 contrasts. We categorized a gene as part of the shared component if it had Mashr posterior probability greater  
843 than 0.01.

844

### 845 **Construction of Correlation Matrix**

846 To calculate the correlation matrix, we used a systematic approach to quantify the relationships between  
847 genetic estimates across different neuropsychiatric and neurodegenerative disorders. Spearman correlation  
848 coefficients were calculated to assess the strength and direction of association between genetic estimates  
849 across different disorders. The calculation was performed for the common to each pair of disorders, grouped  
850 by assay, after the exclusion of the shared disease signatures.

851

852 The wide-format correlation matrix was converted to a matrix suitable for heatmap visualization. Missing  
values were replaced with zeros. Annotations indicating the number of significant genes were added to the



853 rows and columns using the `rowAnnotation` and `HeatmapAnnotation` functions from the  
854 `ComplexHeatmap` package. The heatmap was generated with hierarchical clustering of both rows and  
855 columns, and colored based on the Spearman correlation values using a gradient from blue (negative  
856 correlation) to red (positive correlation).

857

### 858 **Co-heritability analysis**

859 We employed cross-trait LD score regression using the LDSC tool<sup>139</sup> to estimate the genetic correlation  
860 between a pair of traits. We used summary stats for the following GWAS traits (AD<sup>11</sup>, DLBD<sup>140</sup>, PD<sup>13</sup>, FTD<sup>141</sup>,  
861 SCZ<sup>18</sup>, BD<sup>19</sup>) and calculated heritability for each of the traits and the genetic covariance and correlation  
862 between each of the pair of traits (in total 15 pairs of traits). The size of the cohort was provided to the function  
863 `munge_sumstats.py` for heritability estimates. Precomputed LD scores for 1000 Genomes EUR data were  
864 downloaded from [https://data.broadinstitute.org/alkesgroup/LDSCORE/eur\\_w\\_ld\\_chr.tar.bz2](https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2). The SNP list for  
865 `munge_sumstats.py` was downloaded from  
866 [https://data.broadinstitute.org/alkesgroup/LDSCORE/w\\_hm3.snplist.bz2](https://data.broadinstitute.org/alkesgroup/LDSCORE/w_hm3.snplist.bz2). Standard error was obtained from the  
867 LDSC output. Script `munge_sumstats.py` was modified to include the parameter: `--chunksize 5e5`.

868 For each of the 15 possible combinations of traits, we calculated the level of correlation of gene expression  
869 using the Spearman rank correlation test. Genes were selected by applying the following criteria:  $\log_{2}FC \geq 0.5$ ,  
870  $FDR \geq 0.05$ . Co-expression coefficient was calculated for the overall dataset and for each of the cell types.  
871 Next, to correlate co-expression and co-heritability, we calculated Spearman rank correlation coefficient  
872 between LDSC genetic correlation score and co-expression coefficient using 15 possible combinations of traits  
873 as data points for the Spearman rank correlation. Spearman was calculated for the overall dataset providing  
874 the genetic estimates of the expression similarities in the PsychAD cohort, and also per cell type to obtain the  
875 ranking of the cell types that contribute the most to the genetic to transcriptomic similarity in PsychAD.

876

### 877 **Mediation analysis**

878 Causal Mediation Analysis was performed using two R packages; `mediation` and `psych`. Results were  
879 cross-validated between the two methods (identical within a threshold) to ensure the estimated coefficients,  
880 and the mediation effects are statistically robust. From 696 individuals in AD contrast, we subsetted 645  
881 individuals with European ancestry who have PRS calculations from the latest AD GWAS<sup>11</sup>. For each  
882 regression, we used the following covariates:

883

884 `Age + Sex + PMI + PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + PC8 + PC9 + PC10`

885

886 where PC1-10 indicate genotype PCs. For subclass proportion, we used CLR-transformed cell count fractions  
887 from `crumblr` analysis. For bootstrapping, we used 10,000 simulations with 50th percentile of the treatment  
888 variable used as the control condition and 90th percentile of the treatment variable used as the treatment  
889 condition.

890

### 891 **Trajectory analysis using VAE model**

892

893 **Rationale.** Traditionally, changes in gene expression as a function of disease state are measured using linear-  
894 based models. This approach has proven highly valuable and has enhanced our understanding of the  
895 biological mechanisms underlying many diseases. However, it is increasingly recognized that changes in gene  
896 expression can be highly nonlinear<sup>60</sup>; the interaction among numerous signaling pathways, many involving  
897 multiple feedback loops, can lead to complex dynamics that linear models may fail to capture. One approach to  
898 capturing potentially nonlinear changes in gene expression is pseudotime analysis (i.e., trajectory  
899 inference)<sup>142,143</sup>. In this approach, cells are assigned a relative pseudotime based on a metric that measures

900 the distance between gene expression vectors, coupled with specific assumptions about how trajectories can  
901 evolve. However, this approach requires prior assumptions that might obscure informative aspects of disease  
902 progression. For example, most methods require a dimensionality reduction operation (e.g., PCA or UMAP)  
903 before calculating each cell's nearest neighbors. The variance of lowly expressed genes, regardless of their  
904 importance to the disease, can be overshadowed by the variance of genes with greater expression but less  
905 relevance, or by the variance inherent in a sample from a highly diverse demographic. Furthermore, in the  
906 case of AD, it is known that the spread of neurofibrillary tangles and A $\beta$  plaques is strongly, but not perfectly,  
907 correlated with dementia. Of special interest is understanding cases where individuals are resilient to dementia  
908 despite a high neurofibrillary tangle or A $\beta$  plaque burden. Thus, we aimed to disentangle changes in gene  
909 expression associated with disease burden from those associated with the onset of dementia. Standard  
910 pseudotime analysis does not allow us to separate these two covariates effectively. To capture the potentially  
911 nonlinear gene expression dynamics during the course of AD progression and to disentangle the effects of  
912 disease burden and dementia, we used an alternative approach. As detailed below, we employed a VAE to  
913 predict the Braak stage and dementia status from the raw transcript counts of single cells. The model's  
914 predictions of the Braak stage and dementia status were then used as two independent pseudotime axes.  
915 Importantly, we trained the model by equally sampling all combinations of Braak stage and dementia status,  
916 thereby discouraging the model from learning spurious correlations between the two target variables.

917

918 **Model architecture.** We used a VAE, based on the scVI model<sup>144</sup>, to predict the Braak stage and dementia  
919 status from single-cell gene counts. Both the gene encoder and decoder contained two 512-dimensional  
920 hidden layers. All hidden layers applied the ReLU activation function before a LayerNorm operation. Model  
921 predictions for Braak and dementia were generated using linear functions from the 32-dimensional latent layer.

922 **Model training.** Single-cell gene counts were log<sub>1p</sub> transformed in the input layer, and top 25,000 genes for  
923 each cell class, based on the percentage of cells the gene was expressed, were used for training. Genes found  
924 in the X or Y chromosomes were excluded to discourage the model from learning sex specific differences. The  
925 network was trained to minimize 1) the gene reconstruction loss, 2) the Kullback-Leiber divergence, and 3) the  
926 disease target prediction (Braak and dementia) loss:

927 
$$\mathcal{L} = \alpha(\mathcal{L}_{gene} + \mathcal{L}_{KL}) + \mathcal{L}_{target},$$

928 The scalar  $\alpha$  was calibrated to properly weigh the contribution of the standard VAE loss terms (i.e., the gene  
929 reconstructions and KL losses) and the target and covariate prediction loss (see below). The gene  
930 reconstruction loss,  $\mathcal{L}_{gene}$ , was the zero-inflated negative binomial<sup>144</sup>. For the binary target dementia, the  
931 softmax function was applied to the output, and the loss was the cross-entropy. For Braak, target values were  
932 first normalized to zero mean and unit standard deviation, and the mean-squared error loss was used. All loss  
933 terms were trained simultaneously. To prevent the model from overfitting the data, we applied a dropout with  
934 0.25 probability in the input layer (after the log<sub>1p</sub> transform) and with probability of 0.5 to all hidden layers (after  
935 the ReLU and LayerNorm operations). For each cell class, we divided the cells into 10 splits. In each split, 90%  
936 of the cells were used for training, and the remaining 10% were used for inference. Within each split, cells from  
937 a single donor exclusively belonged to either the training set or the inference set, but never both. Thus, model  
938 predictions were always based on cross-validated data from different donors. We trained one model for each of  
939 the ten splits to generate predictions for all donors for that cell class. Models were trained using all donors from  
940 the MSSM and RADC brain sources, and then ran inference on only the 696 donors that focused on the AD  
941 phenotype contrast (**Fig. 1d**). There existed different numbers of cells for each cell class, thus the amount of  
942 training differed between classes. For neurons, astrocytes, oligodendrocytes and the immune cell class, we  
943 trained for 5 epochs, and then calculated the Braak and dementia model predictions by averaging the  
944 inference outputs generated from the last two epochs. For mural and endothelial cells, which contained less  
945 data, we trained for 15 and 20 epochs, respectively, and calculated the Braak and dementia model predictions  
946 by averaging the outputs generated from the last five epochs. Model accuracy for the OPC cell class evolved

947 more slowly over model training; thus, we also trained this cell class for 15 epochs, and calculated the Braak  
948 and dementia model predictions by averaging the outputs generated from the last five epochs. We used  
949 empirical testing to determine which values of  $\alpha$  generated accurate Braak and dementia model predictions.  
950 Immune cells typically have reduced mean gene counts compared to the other cell classes, and we found that  
951 setting  $\alpha = 0.005$ . For all other cell classes, in which mean gene counts were on average greater, we set  
952  $\alpha = 0.002$ . Network parameters were trained using the AdamW optimizer<sup>145</sup> with parameters  $\beta_1 = 0.9$ ,  
953  $\beta_2 = 0.998$ ,  $\epsilon = 1e - 7$  and weight decay of 0.05 applied to all layers before the latent layer. We used a  
954 batch size of 512, and a learning rate schedule with a warmup and decay period using the formula  
955  $lr_{rate} = d^{-0.5} \cdot \min(n^{-0.5}, n \cdot warmup^{-1.5})$ , where we set  $d = 5e - 4$ ,  $warmup = 2000$ , while  $n$  is the  
956 current training step. Finally, we clipped the gradient norm to 0.25 to stabilize training.

957

958 **Model accuracy.** We averaged the cell-level Braak and dementia model predictions to obtain donor-averaged  
959 scores. For dementia, we calculated the balanced classification score by determining the percentage of donors  
960 without dementia with a prediction score  $\leq 0.5$ , the percentage of donors with dementia with a prediction score  
961  $> 0.5$ , and then averaging these two values. For Braak, we calculated the Pearson R value between the actual  
962 Braak stage and the Braak predictions. Error bars were generated using a bootstrap procedure, in which we  
963 randomly sampled donors (with replacement), calculated the Braak and dementia prediction accuracy, and  
964 repeated this process 20,000 times. For each cell class, we included all donors with at least 5 cells.

965

966 **Disentangling Braak and dementia.** Braak stage and dementia status are significantly correlated (Pearson R  
967 = 0.582,  $P < 1e-60$ ). This strong correlation between target variables implies that input features (i.e., changes  
968 in gene expression) associated with the two target variables are also likely to be correlated, which makes it  
969 challenging for the model to learn which input feature is predictive of which target variable. The result is when  
970 the model is trained in a standard fashion, the correlation between the Braak and dementia model predictions  
971 are close to 1 (**Supplementary Fig. 7a**, Immune class shown), suggesting that the model has learned spurious  
972 correlations between the input features and target variables. Fully removing spurious correlation in machine  
973 learning models is still an unresolved question. However, balancing the training data, such that each of the 14  
974 combinations of Braak and Dementia (7 Braak values X 2 Dementia values) are equally sampled, can  
975 effectively reduce spurious correlations learned during training<sup>146</sup>. In practice, we equally sampled from 15  
976 groups, in which the extra group consisted of donors whose Braak stage or dementia status had not been  
977 determined. Training with group balancing reduced the correlation between the predicted Braak and dementia  
978 values (**Supplementary Fig. 7b**), did not adversely affect the model accuracy at the donor-level  
979 (**Supplementary Fig. 7c**).

980

981 **Calculating gene trajectories.** We wished to measure how gene expression varied as a function of the  
982 predicted Braak stage. First, gene counts were normalized so that each cell's total count was 10,000, followed  
983 by the log1p transformation. Second, for each cell class and each donor, we calculated the mean predicted  
984 Braak stage, and the mean normalized expression for each gene. Averaging within each donor reduced  
985 variability and ensured that donors with greater cell counts did not contribute disproportionately in downstream  
986 analysis. Third, we smoothed both the predicted donor-averaged Braak scores, and the donor-averaged gene  
987 expression with a Gaussian kernel (**Supplementary Fig. 8**). Specifically, for each donor  $i$ , we weighted all  
988 other donors  $j$  as

$$w_{i,j} = Z_i \exp\left(-\frac{(\hat{b}_j - \hat{b}_i)^2}{2\sigma^2}\right)$$

989

990 where  $\hat{b}_i$  is the predicted Braak score of donor  $i$ ,  $\sigma^2$  was set to half the variance of the predicted Braak  
991 distribution, and the normalization term  $Z_i$  was set such that  $\sum_j w_{i,j} = 1$ . This allowed us to calculate  
992 smoothed Braak,  $\tilde{b}_i$  and gene expression,  $\tilde{\mathbf{g}}_i$ , values

$$\tilde{b}_i = \sum_j w_{i,j} \hat{b}_j$$
$$\tilde{\mathbf{g}}_i = \sum_j w_{i,j} \mathbf{g}_j$$

994 where  $\mathbf{g}_i$  is the gene expression vector of log1p normalized counts for donor  $i$ . After ordering the smoothed  
995 Braak scores, Braak gene trajectories are now represented as the tuple

$$(\tilde{b}_i, \tilde{\mathbf{g}}_i)$$

997  
998 We only included donors with at least 5 cells for the cell class. We also removed the 10 donors with the least  
999 and greatest smoothed predicted Braak scores after smoothing to minimize the edge effects from smoothing.

1000

1001 **Resilience against dementia.** Since tau proteinopathy and dementia status are highly correlated, gene  
1002 expression as a function of the two variables is also correlated, and thus partially redundant. Therefore, we  
1003 aimed to measure how gene expression covaried with predicted dementia given the predicted Braak staging.  
1004 To do so, we first calculated the expected predicted dementia and expected gene expression for donors with  
1005 similar Braak staging. Specifically, we defined the expected dementia given Braak,  $d_i^b$ , and the expected gene  
1006 expression given Braak,  $\mathbf{g}_i^b$ ,

$$d_i^b = \sum_j w_{i,j} \hat{b}_j$$
$$\mathbf{g}_i^b = \sum_j w_{i,j} \mathbf{g}_j$$

1008

1009 The only modification to the kernel was that we set  $w_{i,i} = 0$  so that each donor doesn't contribute to its own  
1010 expected value. We then calculated the residuals between the donor's predicted dementia status and gene  
1011 expression with its expected values:

$$d_i^R = d_i - d_i^b$$
$$\mathbf{g}_i^R = \mathbf{g}_i - \mathbf{g}_i^b$$

1013

1014 The dementia resilience score for each donor was then the product of these two terms. When calculating early  
1015 and late resilience, donors were separated into early and late groups based on their predicted Braak staging  
1016 before averaging within each group. Using this metric, we define genes as protective if gene expression  
1017 increases as predicted dementia decreases, given the predicted Braak staging (i.e., the product of the terms  
1018 defined above is negative). Conversely, we define genes as damaging if gene expression increases as  
1019 predicted dementia increases, given the predicted Braak staging.

1020

1021 **Trajectory nonlinearity.** We were interested in measuring how gene expression potentially changes in a  
1022 nonlinear manner as a function of Braak or dementia. As an initial step, we first wished to quantify the degree  
1023 of nonlinearity in gene trajectories across the different cell classes. As outlined in **Supplementary Fig. 8**, this  
1024 calculation was performed across a series of steps. Starting with the gene trajectories for each gene and each  
1025 cell class as described above, in which smoothed gene expression varied as a function of predicted Braak, we  
1026 fit each one with a linear fit, and then calculated its explained variance. We calculated the mean explained  
1027 variance using all genes within each cell class with mean normalized expression above 0.01 and used this  
1028 value as a baseline. Next, we fit each trajectory with a piecewise linear fit consisting of two consecutive linear  
1029 segments, separated at some predicted Braak score  $\tilde{b} = t$ . For each cell class, we determined the optimal  $t$   
1030 that maximized the explained variance of the piecewise fits for all genes within that cell class. The nonlinearity



1031 index (**Fig. 7b, bottom**) was then defined as the difference in explained variance between the piecewise linear  
1032 fit and the linear fit. Error bars were determined by bootstrapping the model fits, in which we randomly sampled  
1033 genes from donors (with replacement), calculating the nonlinearity index, and repeating the process 100 times.  
1034 Significance between different cell classes was calculated by comparing the 100 x 100 bootstrapped nonlinear  
1035 index values. We used the optimal time  $t$  was then used to define an "early" and "late" period. For the Immune  
1036 cell class, which had the greatest nonlinearity index, the early period was defined as the first 140 donors with  
1037 the lowest Braak model predictions (after the first 10 donors were removed to account for edge effects, see  
1038 above). For the other cell classes, we adjusted 140 proportionally based on the number of donors for that cell  
1039 class and defined this number as  $N$ ; the early period for each cell class was then defined as the  $N$  donors with  
1040 the lowest Braak model predictions. Since the rank ordering of donor-averaged Braak scores varies between  
1041 cell classes, donors may be classified as early stage for some cell classes and late stage for others.

1042  
1043 **Trajectory gene enrichment.** We wished to determine which genetic pathways were most significantly up or  
1044 down-regulated during the progression of AD. To do so, we first extracted the slopes of the "early" and "late"  
1045 linear fits for the Braak trajectories, and the mean early and late resilience scores (defined above). We used  
1046 these slopes input to Zenith (<https://bioconductor.org/packages/release/bioc/html/zenith.html>) to calculate the  
1047 changes across all GO BP pathways across the eight cell classes. For each GO BP pathway, we calculated  
1048 the maximum  $-\log_{10}(\text{FDR})$  score across the eight cell classes and across early and late Braak and Dementia  
1049 stages. The score of each pathway was assigned this maximum value.  
1050 To obtain a condensed list of the most significantly genetic pathways, we first selected all pathways with  $\text{FDR} \leq$   
1051 0.05. Next, since we were only interested in pathways that could be informative of the mechanisms underlying  
1052 AD progression, we excluded pathways containing words referring to overly broad behaviors or cognitive  
1053 functions ("learning", "memory", "vocalization", "social", "auditory", "startle response", "behavior", "locomotor",  
1054 "startle", "prepulse inhibition"), terms referring to anatomical structures other than the cortex ("substantia nigra  
1055 development", "cardiac", "coronary", "aortic", "ventricular", "kidney", "metanephric", "retina", "optic", "bone",  
1056 "respiratory", "pulmonary", "olfactory", "sperm", "placenta", "egg", "embryonic", "ovulation", "estrous",  
1057 "placenta", "sperm", "mammary", "germ layer", "outflow tract septum", "adrenal", "epithelial", "skeletal", "otic",  
1058 "head") or overly broad neural terms ("nervous system process", "cerebral cortex", "recognition", "host",  
1059 "organ", "developmental growth"). To condense the remaining pathways into a more manageable size, we  
1060 used rrvgo (<https://www.bioconductor.org/packages/release/bioc/html/rrvgo.html>). We selected the Wang  
1061 semantic similarity metric<sup>147</sup>, and set the threshold at 0.9 to obtain 56 GO BP pathways (**Supplementary Fig.**  
1062 **9**). For easier visualization, we selected 32 representative pathways from this set for **Fig 7c**. We also  
1063 performed similar steps (pathways with minimum  $\text{FDR} < 0.05$  included, Wang metric with threshold at 0.9) to  
1064 obtain the top GO Molecular Function and Cellular Component (**Supplementary Figs. 10, 11**) pathways. In all  
1065 cases, we only included pathways with at least 10 genes to ensure that results were statistically robust, and no  
1066 more than 250 genes to ensure that pathways were not overly broad.

1067  
1068 **Mean trajectories and MAGMA enrichment.** For both the mean normalized expression (**Fig. 7d**) and Magma  
1069 enrichment analysis (**Fig. 7f**), we used the top 250 coding genes based upon the early and late slopes of the  
1070 Braak trajectories. Late decreasing genes tend to also appear to contain an early increase (**Fig. 7d**). However,  
1071 we cannot say whether this is biologically meaningful or the result of selection bias, as a strong late decrease  
1072 must be preceded by a high baseline. For both the mean expression and Magma enrichment calculations,  
1073 results were qualitatively similar if we used the top 500 or 1000 genes instead (data not shown).



## 1074 **Data availability**

1075 All data are available via the AD Knowledge Portal (<https://adknowledgeportal.org>). The AD Knowledge Portal  
1076 is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership  
1077 (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to  
1078 enable open-science practices and accelerate translational learning. The data, analyses and tools are shared  
1079 early in the research cycle without a publication embargo on secondary use. Data is available for general  
1080 research use according to the following requirements for data access and data attribution  
1081 (<https://adknowledgeportal.synapse.org/Data%20Access>). The data are available under controlled use  
1082 conditions set by human privacy regulations. To access the data, a data use agreement is needed. The  
1083 registration is in place solely to ensure the anonymity of the study participants. In addition, we have a data  
1084 descriptor manuscript<sup>102</sup> detailing the data processing and data collection.

## 1085 **Code availability**

1086 All the source codes used in this study are available via GitHub  
1087 <https://github.com/DiseaseNeuroGenomics/PsychADxD>.

## 1088 **Acknowledgments**

1089 We would like to express our deep gratitude to the patients and their families who generously donated the  
1090 invaluable biological material essential for the success of this study. We are profoundly indebted to their  
1091 participation and commitment to advancing scientific knowledge and improving human health. We  
1092 acknowledge the National Institute on Aging for their generous support in funding this research with the  
1093 following NIH grants: R01AG067025, R01AG082185, and R01AG065582. Human tissues were obtained from  
1094 the NIH NeuroBioBank at the Mount Sinai Brain Bank (MSSM; supported by NIMH-75N95019C00049), the  
1095 Rush Alzheimer's Disease Center (RADC; funding: P30AG10161, P30AG72975, R01AG15819, R01AG17917,  
1096 R01AG22018, U01AG46152, and U01AG61356), and NIMH-IRP Human Brain Collection Core (HBCC, project  
1097 # ZIC MH002903). This work was also supported by the Novo Nordisk Foundation NNF14CC0001 and  
1098 NNF20SA0035590. The results published here are in whole or in part based on data obtained from the AD  
1099 Knowledge Portal.

## 1100 **Author contributions**

1101 Conceptualization: PR, VH, JFF, DL  
1102 Methodology: PR, JFF, DL, GEH  
1103 Software: GEH, DL, NYM  
1104 Validation: DL, XW, JMF, JFF, PK  
1105 Formal analysis: DL, MK, NYM, GEH, SK, MP, TC, FT  
1106 Investigation: JFF, AH, CC, ZS, MA, SA, XW, JMF  
1107 Resources: VH, DAB, SM, LLB, PKA  
1108 Data Curation: JB, PNM, DM, DB, KT, DL  
1109 Writing: DL, PR, JFF, NYM with supports from all co-authors.  
1110 Visualization: DL, MK, NYM  
1111 Supervision: PR, DL, JFF, JB, VH, GV, KG, LJJ  
1112 Project administration: DL, PR  
1113 Funding acquisition: PR, VH

1114 All authors read and approved the final draft of the paper.

1115 **Competing interests declaration**

1116 The authors declare no competing interests.

1117 **Materials & Correspondence**

1118 Correspondence to Donghoon Lee or Panos Roussos.

## 1119 **Supplementary Information**

### 1120 **PsychAD Consortium Authors**

1121 Aram Hong (1, 4, 6, 7); Athan Z. Li (10, 12); Biao Zeng (1, 4, 6, 7); Chenfeng He (9, 12); Chirag Gupta (9, 12);  
1122 Christian Porras (1, 4, 6, 7); Clara Casey (1, 4, 6, 7); Colleen A. McClung (18); Collin Spencer (1, 4, 6, 7);  
1123 Daifeng Wang (9, 10, 12); David A. Bennett (19); David Burstein (1, 2, 4, 6, 7, 8); Deepika Mathur (1, 4, 6, 7);  
1124 Donghoon Lee (1, 4, 6, 7); Fotios Tsetsos (1, 2, 4, 6, 7); Gabriel E. Hoffman (1, 2, 4, 6, 7, 8); Genadi Ryan (13,  
1125 17); Georgios Voloudakis (1, 2, 3, 4, 6, 7, 8); Hui Yang (1, 4, 6, 7); Jaroslav Bendl (1, 4, 6, 7); Jerome J. Choi  
1126 (11, 12); John F. Fullard (1, 4, 6, 7); Kalpana H. Arachchilage (9, 12); Karen Therrien (1, 4, 6, 7); Kiran Girdhar  
1127 (1, 4, 6, 7); Lars J. Jensen (21); Lisa L. Barnes (19); Logan C. Dumitrescu (22, 23); Lyra Sheu (1, 4, 6, 7);  
1128 Madeline R. Scott (18); Marcela Alvia (1, 4, 6, 7); Marios Anyfantakis (1, 4, 6, 7); Maxim Signaevsky (6, 7);  
1129 Mikaela Koutrouli (1, 4, 6, 7, 21); Milos Pjanic (1, 4, 6, 7); Monika Ahirwar (13, 17); Nicolas Y. Masse (1, 4, 6,  
1130 7); Noah Cohen Kalafut (10, 12); Panos Roussos (1, 2, 4, 6, 7, 8); Pavan K. Auluck (20); Pavel Katsel (6);  
1131 Pengfei Dong (1, 4, 6, 7); Pramod B. Chandrashekar (9, 12); Prashant N.M. (1, 4, 6, 7); Rachel Bercovitch (1,  
1132 4, 6, 7); Roman Kosoy (1, 4, 6, 7); Sanan Venkatesh (1, 2, 4, 6, 7); Saniya Khullar (9, 12); Sayali A. Alatar  
1133 (10, 12); Seon Kinrot (1, 4, 6, 7); Stathis Argyriou (1, 4, 6, 7); Stefano Marenco (20); Steven Finkbeiner (13, 14,  
1134 15, 16, 17); Steven P. Kleopoulos (1, 4, 6, 7); Tereza Clarence (1, 4, 6, 7); Timothy J. Hohman (22, 23); Ting  
1135 Jin (9, 12); Vahram Haroutunian (5, 6, 7, 8); Vivek G. Ramaswamy (13, 17); Xiang Huang (12); Xinyi Wang (1,  
1136 4, 6, 7); Zhenyi Wu (1, 4, 6, 7); Zhiping Shao (1, 4, 6, 7)


1137

### 1138 **PsychAD Consortium Affiliations**

1139 1: Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA  
1140 2: Center for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx,  
1141 NY, USA  
1142 3: Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York,  
1143 NY, USA  
1144 4: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,  
1145 USA  
1146 5: Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA  
1147 6: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA  
1148 7: Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA  
1149 8: Mental Illness Research, Education and Clinical Center VISN2, James J. Peters VA Medical Center, Bronx,  
1150 NY, USA  
1151 9: Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA  
1152 10: Department of Computer Sciences, University of Wisconsin-Madison, Madison, WI, USA  
1153 11: Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, USA  
1154 12: Waisman Center, University of Wisconsin-Madison, Madison, WI, USA  
1155 13: Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA, USA  
1156 14: Department of Neurology, University of California San Francisco, San Francisco, CA, USA  
1157 15: Department of Physiology, University of California San Francisco, San Francisco, CA, USA  
1158 16: Neuroscience and Biomedical Sciences Graduate Programs, University of California San Francisco, San  
1159 Francisco, CA, USA  
1160 17: Taube/Koret Center for Neurodegenerative Disease Research, Gladstone Institutes, San Francisco, CA,  
1161 USA  
1162 18: Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA  
1163 19: Rush Alzheimer's Disease Center and Department of Neurological Sciences, Rush University Medical  
1164 Center, Chicago, IL, USA


- 1165 20: Human Brain Collection Core, National Institute of Mental Health-Intramural Research Program, Bethesda,  
1166 MD, USA
- 1167 21: Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University  
1168 of Copenhagen, Copenhagen, Denmark
- 1169 22: Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
- 1170 23: Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA

1171 **Supplementary Figures**



1172 **Supplementary Fig. 1.** (a) Extended schematic overview of snRNA-seq experiments leading to unified  
 1173 taxonomy. (b) Donor breakdown by NPS categories and sex. (c) Distribution of gene counts by UMI counts  
 1174 after QC of 6M nuclei. (d) Cumulative nuclei count by percent mitochondrial genes. (e) Histogram of nuclei  
 1175 counts per sample. (f) Distribution of UMI counts per sample. (g) Distribution of gene counts per sample. (h)  
 1176 Distribution of nuclei count per sample. (i) Distribution of nuclei count per donor. (j) Treemap showing the color  
 1177 scheme of the unified taxonomy.  
 1178  
 1179





1180

1181

1182

1183


1184

1185

1186


**Supplementary Fig. 2.** (a) Composition of cell types in each brain bank using class and subclass-level cellular taxonomy. (b) Composition of subtype in each brain bank. (c) Clustering of EN lineage. A UMAP focusing on the diversity of 10 subtypes of excitatory neurons. (d) Clustering of IN lineage. A UMAP focusing on the diversity of 7 subclasses of inhibitory neurons (IN). (e) Spatial distribution of IN subclass. (f) Expression and fraction of marker gene expression in 27 subclasses. Expression z-scaled and averaged across nuclei. (g) Comparison of subclass-level cellular taxonomy with Ma et al 2022. (h) Comparison of subtype-level cellular

1187 taxonomy with Mathys et al 2023. **(i)** Disease enrichment scores based on GWAS (scDRS) for AD, PD, SCZ,  
 1188 and BD.  
 1189




1190  
 1191 **Supplementary Fig. 3.** **(a)** Example of a gene with the highest variation across age. **(b)** Example of a gene  
 1192 with the highest variation across genetic ancestry. **(c)** Example of a gene with the highest variation across sex.  
 1193 **(d)** Example of a gene with the highest variation across brain banks. **(e)** Example of a gene with the highest  
 1194 variation across diagnosis. **(f)** Normalized expression of ARL17B gene within EN\_L2\_3\_IT subclass stratified  
 1195 by genetic ancestry. **(g)** The logistic regression coefficient for PD risk using the haplotype of MAPT locus. **(h)**

1196 Spearman correlation test between variance explained by inter-individual variation and average LOEUF  
 1197 conservation score.  
 1198



1199  
 1200 **Supplementary Fig. 4.** Cross-disorder variation of cell type composition comparing 8 different NDDs and  
 1201 NPDs against common neurotypical controls. **(a)** Correlation matrix showing the relationships between various


1202 clinical and demographic variables for the selection of the covariates. The color intensity indicates the strength  
 1203 of the correlation, with red representing positive correlations and blue negative correlations. **(b)** Variance  
 1204 partition of cell type composition, displaying the variance captured by different covariates in the formula. **(c)**  
 1205 Bar plot depicting the absolute logFC values of the 8 different NDDs and NPDs across the cell types. **(d)**  
 1206 Variation in cell type composition for each subtype in 8 different diseases. NDDs and NPDs indicate meta-  
 1207 analysis using broad disease categories. Color intensity indicates effect size and dot size reflects the statistical  
 1208 significance of correlations.  
 1209




1210  
 1211 **Supplementary Fig. 5. Cross-disorder gene expression signature. (a)** GO BP pathways implicated by shared  
 1212 gene expression changes across 8 disorders using Zenith. T-statistic values indicate the direction and

1213 magnitude of the gene set enrichment. **(b)** Extended data for **Fig. 5a** with all 27 subclasses and without  
1214 reduction in similar GO terms. **(c)** Pathways implicated by shared signatures from AD, DLBD, Vas, and PD. **(d)**  
1215 Correlation between shared heritability and transcriptome similarity per cell subclass.  
1216






1218 **Supplementary Fig. 6.** Transcriptomic changes across AD neuropathology. **(a)** Extended data for **Fig. 6a.**  
 1219 Compositional variation analysis using normal aging, different measures of AD pathology (binary AD diagnosis  
 1220 (dx\_AD), CERAD score, Braak staging, and ordinal dementia scale), and 3 categories of NPS within AD. **(b)**  
 1221 Age distribution of AD cases with or without three NPS categories. **(c)** Mean effect sizes aggregated by  
 1222 direction of effect per cell class. **(d)** Extended data for **Fig. 6d.** DEGs in AD phenotypes. Meta-analysis  
 1223 between brain banks. Top genes with FDR < 0.01 and effect size  $\geq 0.35$ . **(e)** Functional enrichment analysis of  
 1224 DEGs by subclass using Gene Ontology Biological Process. Hypergeometric test with FDR  $\leq 0.01$  shown.  
 1225



1226 **Supplementary Fig. 7.** The effect of different training methods on model prediction correlations and accuracy  
 1227 for the Immune cell class. **(a)** Correlation between Braak (x-axis) and dementia (y-axis) model predictions at  
 1228 the cell-level (left panel) and donor-averaged level (right panel) when all cells are equally sampled. To reduce  
 1229 the figure size, only 1 out of 20 cells shown in the left panel. **(b)** Same as (a), except that all combinations of  
 1230 Braak stage and dementia status are equally sampled during training. This has the effect of reducing the  
 1231 correlation between the predicted Braak and dementia values. **(c)** The correlation between the actual and  
 1232 predicted Braak values (left panel) and dementia classification accuracy (right panel), both measured at the  
 1233 donor-averaged level, are shown for the two training methods.  
 1234  
 1235




1236 **Supplementary Fig. 8.** The steps involved in calculating the Braak trajectory for an example gene - NAV2  
 1237 from the Immune cell class. **(a)** Given cell-based model predictions along with normalized gene counts, we can  
 1238 calculate the donor-averaged predicted Braak (x-axis), predicted dementia (y-axis), and normalized gene  
 1239 counts (hue). Predicted Braak and dementia values are normalized between 0 and 1. We then smooth the  
 1240 predicted Braak scores along with the gene counts with a Gaussian kernel (black curve, width is shown at  
 1241 scale). **(b)** After smoothing, we obtain the Braak trajectory for this gene, relating gene expression to the  
 1242

1243 predicted Braak value. **(c)** We then compare how well we can fit this trajectory with a single linear model (blue  
1244 dashed line) and a piecewise linear model (green dashed line). The piecewise linear model consists of two  
1245 consecutive linear fits, in which the transition point has been optimized to maximize the explained variance.  
1246 This transition point is then used to define an "early" and "late" disease stages (**Methods**).  
1247




1249 **Supplementary Fig. 9.** Extended data for **Fig. 7c.** Expanded list of all 56 GO BP pathways. Upper left  
 1250 triangles indicate the early phases, and lower right triangles indicate the late phases of the AD trajectory  
 1251 predicted by Braak and dementia resilience. Hue indicates the z-score, and stars indicate FDR < 0.05.  
 1252



1253 **Supplementary Fig. 10.** Pathway enrichment using the top GO Cellular Components pathways. Upper left  
 1254 triangles indicate the early phases, and lower right triangles indicate the late phases of the AD trajectory  
 1255 predicted by Braak and dementia resilience. Hue indicates the z-score, and stars indicate FDR < 0.05.  
 1256  
 1257







1263

1264

**Supplementary Fig. 12.** GO BP pathways and GWAS enrichment results for dementia resilience. **(a)** Top

1265

early protective pathways (i.e. resilience against dementia, blue), early damaging (i.e. associated with

1266

dementia, orange), late protective (green) and late damaging (red). Hue indicates the number of genes in the

1267

pathway. Negative log FDR clipped at 10. **(b)** Enrichment of heritability estimates (MAGMA) for each disease


1268

trajectory module. Text color indicates neurological traits (light red) and psychiatric traits (cyan). Hue indicates


1269

negative log<sub>10</sub>(FDR), asterisk indicates FDR < 0.05. Negative log FDR clipped at 5.

1270



1271  
 1272 **Supplementary Fig. 13.** GO BP pathways and GWAS enrichment results for the EN cell class based on their  
 1273 response to Braak (a,b) and dementia resilience (c,d). **(a)** Pathway enrichment of genes with early increasing  
 1274 response to increasing tau proteinopathy (blue), early decreasing (orange), late increasing (green) and late  
 1275 decreasing (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)**  
 1276 Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates  
 1277 neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log<sub>10</sub>(FDR), asterisk  
 1278 indicates FDR < 0.05. Negative log FDR clipped at 5. **(c)** Pathway enrichment of genes with early protective  
 1279 resilience against dementia (blue), early damaging associated with dementia (orange), late protective (green),  
 1280 and late damaging (red). **(d)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module.  
 1281



1282

1283

**Supplementary Fig. 14.** GO BP pathways and GWAS enrichment results for the IN cell class based on their response to Braak (a,b) and dementia resilience (c,d). **(a)** Pathway enrichment of genes with early increasing

1284

response to increasing tau proteinopathy (blue), early decreasing (orange), late increasing (green) and late

1285

decreasing (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)**

1286

Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates

1287

neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log<sub>10</sub>(FDR), asterisk

1288

indicates FDR < 0.05. Negative log FDR clipped at 5. **(c)** Pathway enrichment of genes with early protective

1289


resilience against dementia (blue), early damaging associated with dementia (orange), late protective (green),

1290

and late damaging (red). **(d)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module.

1291

1292



1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

**Supplementary Fig. 15.** GO BP pathways and GWAS enrichment results for the OPC cell class based on their response to Braak (a,b) and dementia resilience (c,d). **(a)** Pathway enrichment of genes with early increasing response to increasing tau proteinopathy (blue), early decreasing (orange), late increasing (green) and late decreasing (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log<sub>10</sub>(FDR), asterisk indicates FDR < 0.05. Negative log FDR clipped at 5. **(c)** Pathway enrichment of genes with early protective resilience against dementia (blue), early damaging associated with dementia (orange), late protective (green), and late damaging (red). **(d)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module.



## 1303 **Supplementary Tables**

1304 **Supplementary Table 1.** Clinical and technical metadata of 1,494 donors in the PsychAD cohort. Metadata  
1305 includes binary contrasts and continuous variables used in the study.

1306  
1307 **Supplementary Table 2.** Hierarchical cellular taxonomy of the PsychAD snRNA-seq data. Metadata including  
1308 parent-child relationships, color hex codes, and number of nuclei per subtype.

1309  
1310 **Supplementary Table 3.** Compositional variation analysis across 8 cross-disorder traits.

1311  
1312 **Supplementary Table 4.** Differentially expressed genes across 8 cross-disorder traits.

1313  
1314 **Supplementary Table 5.** Compositional variation analysis across AD phenotypes.

1315  
1316 **Supplementary Table 6.** Differentially expressed genes across AD phenotypes.

1317  
1318 **Supplementary Table 7.** The top 50 GO BP pathways for each cell class relative to early/late  
1319 increases/decreases in predicted Braak staging, and relative to early/late dementia resilience

1320  
1321 **Supplementary Table 8.** Gene-set enrichment analysis using GWAS summary data for each cell class.  
1322 GWAS scores are calculated using the top 250 coding genes with the greatest slopes measured relative to  
1323 early/late increases/decreases in predicted Braak staging, and the top 250 early/late protective/damaging  
1324 coding genes.

1325  
1326 **Supplementary Table 9.** The top 250 coding genes with the greatest slopes measured relative to early/late  
1327 increases/decreases in predicted Braak staging, and the top 250 early/late protective/damaging coding genes.

1328  
1329 **Supplementary Table 10.** List of gene markers used from Xenium human brain custom panel.

## 1330 **Supplementary Data**

1331 **Supplementary Data 1.** Metadata and model predictions for each cell. Each cell class contains a table that  
1332 includes the cell barcode, donor information, the cell subclass, and both the actual Braak and dementia status  
1333 along with the model predictions.

## 1334 Reference

- 1335 1. Mathys, H. *et al.* Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to  
1336 Alzheimer's disease pathology. *Cell* **186**, 4365–4385.e27 (2023).
- 1337 2. Gabitto, M. I. *et al.* Integrated multimodal cell atlas of Alzheimer's disease. *bioRxiv* 2023.05.08.539485  
1338 (2024) doi:10.1101/2023.05.08.539485.
- 1339 3. Gandal, M. J. *et al.* Shared molecular neuropathology across major psychiatric disorders parallels  
1340 polygenic overlap. *Science* **359**, 693–697 (2018).
- 1341 4. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative diseases.  
1342 *Nat. Commun.* **13**, 4314 (2022).
- 1343 5. Argyriou, S. *et al.* Beyond memory impairment: the complex phenotypic landscape of Alzheimer's disease.  
1344 *Trends Mol. Med.* (2024) doi:10.1016/j.molmed.2024.04.016.
- 1345 6. Ma, S. *et al.* Molecular and cellular evolution of the primate dorsolateral prefrontal cortex. *Science* **377**,  
1346 eabo7257 (2022).
- 1347 7. BRAIN Initiative Cell Census Network (BICCN). A multimodal cell census and atlas of the mammalian  
1348 primary motor cortex. *Nature* **598**, 86–102 (2021).
- 1349 8. Kwan, K. Y., Sestan, N. & Anton, E. S. Transcriptional co-regulation of neuronal migration and laminar  
1350 identity in the neocortex. *Development* **139**, 1535–1546 (2012).
- 1351 9. Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes by integrating single-  
1352 cell RNA-sequencing and human genetics. *Nat. Genet.* **54**, 1479–1492 (2022).
- 1353 10. Zhang, M. J. *et al.* Polygenic enrichment distinguishes disease associations of individual cells in single-cell  
1354 RNA-seq data. *Nat. Genet.* **54**, 1572–1580 (2022).
- 1355 11. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias.  
1356 *Nat. Genet.* **54**, 412–436 (2022).
- 1357 12. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral  
1358 immune cells and microglia in susceptibility. *Science* **365**, (2019).
- 1359 13. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease:  
1360 a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).

- 1361 14. International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address: epilepsy-  
1362 austin@unimelb.edu.au. Genetic determinants of common epilepsies: a meta-analysis of genome-wide  
1363 association studies. *Lancet Neurol.* **13**, 893–903 (2014).
- 1364 15. Dönertaş, H. M., Fabian, D. K., Valenzuela, M. F., Partridge, L. & Thornton, J. M. Common genetic  
1365 associations between age-related diseases. *Nat Aging* **1**, 400–412 (2021).
- 1366 16. Malik, R. *et al.* Genome-wide meta-analysis identifies 3 novel loci associated with stroke. *Ann. Neurol.* **84**,  
1367 934–939 (2018).
- 1368 17. van Rheenen, W. *et al.* Common and rare variant association analyses in amyotrophic lateral sclerosis  
1369 identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nat. Genet.* **53**, 1636–  
1370 1648 (2021).
- 1371 18. Trubetsky, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*  
1372 **604**, 502–508 (2022).
- 1373 19. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases provides new  
1374 insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).
- 1375 20. Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric  
1376 disorders using genome-wide analyses. *Nat. Med.* **29**, 1832–1844 (2023).
- 1377 21. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat. Genet.* **51**,  
1378 431–444 (2019).
- 1379 22. Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture  
1380 and implicate several cognitive domains. *Nat. Genet.* **55**, 198–208 (2023).
- 1381 23. Jansen, P. R. *et al.* Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and  
1382 functional pathways. *Nat. Genet.* **51**, 394–403 (2019).
- 1383 24. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association study of  
1384 educational attainment in 1.1 million individuals. *Nat. Genet.* **50**, 1112–1121 (2018).
- 1385 25. Sniekers, S. *et al.* Genome-wide association meta-analysis of 78,308 individuals identifies new loci and  
1386 genes influencing human intelligence. *Nat. Genet.* **49**, 1107–1112 (2017).
- 1387 26. Sanchez-Roige, S. *et al.* Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders

- 1388 Identification Test (AUDIT) in Two Population-Based Cohorts. *Am. J. Psychiatry* **176**, 107–118 (2019).
- 1389 27. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD  
1390 Collaborative Genetics Association Studies (OC GAS). Revealing the complex genetic architecture of  
1391 obsessive-compulsive disorder using meta-analysis. *Mol. Psychiatry* **23**, 1181–1188 (2018).
- 1392 28. Yu, D. *et al.* Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders  
1393 Through Genome-Wide Association Studies. *Am. J. Psychiatry* **176**, 217–227 (2019).
- 1394 29. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nat. Genet.*  
1395 **51**, 1339–1348 (2019).
- 1396 30. Morris, A. P. *et al.* Large-scale association analysis provides insights into the genetic architecture and  
1397 pathophysiology of type 2 diabetes. *Nat. Genet.* **44**, 981–990 (2012).
- 1398 31. Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274–1283  
1399 (2013).
- 1400 32. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **506**,  
1401 376–381 (2014).
- 1402 33. Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel disease and  
1403 highlight shared genetic risk across populations. *Nat. Genet.* **47**, 979–986 (2015).
- 1404 34. Anderson, C. A. *et al.* Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the  
1405 number of confirmed associations to 47. *Nat. Genet.* **43**, 246–252 (2011).
- 1406 35. das Neves, R. P. *et al.* Connecting variability in global transcription rate to mitochondrial variability. *PLoS*  
1407 *Biol.* **8**, e1000560 (2010).
- 1408 36. Johnston, I. G. *et al.* Mitochondrial variability as a source of extrinsic cellular noise. *PLoS Comput. Biol.* **8**,  
1409 e1002416 (2012).
- 1410 37. Zhu, X., Bühner, C. & Wellmann, S. Cold-inducible proteins CIRP and RBM3, a unique couple with  
1411 activities far beyond the cold. *Cell. Mol. Life Sci.* **73**, 3839–3859 (2016).
- 1412 38. Mouta Carreira, C., Landriscina, M., Bellum, S., Prudovsky, I. & Maciag, T. The comparative release of  
1413 FGF1 by hypoxia and temperature stress. *Growth Factors* **18**, 277–285 (2001).
- 1414 39. Haque, M., Kendal, J. K., Maclsaac, R. M. & Demetrick, D. J. WSB1: from homeostasis to hypoxia. *J.*

- 1415 *Biomed. Sci.* **23**, 61 (2016).
- 1416 40. Dutta, B., Yan, R., Lim, S. K., Tam, J. P. & Sze, S. K. Quantitative profiling of chromatome dynamics  
1417 reveals a novel role for HP1BP3 in hypoxia-induced oncogenesis. *Mol. Cell. Proteomics* **13**, 3236–3249  
1418 (2014).
- 1419 41. Boettger, L. M., Handsaker, R. E., Zody, M. C. & McCarroll, S. A. Structural haplotypes and recent  
1420 evolution of the human 17q21.31 region. *Nat. Genet.* **44**, 881–885 (2012).
- 1421 42. Wade-Martins, R. Genetics: The MAPT locus—a genetic paradigm in disease susceptibility. *Nat. Rev.*  
1422 *Neurol.* **8**, 477–478 (2012).
- 1423 43. Tian, Y. *et al.* Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson’s  
1424 Disease. *Mov. Disord.* **38**, 1813–1821 (2023).
- 1425 44. Català-Senent, J. F. *et al.* A deep transcriptome meta-analysis reveals sex differences in multiple  
1426 sclerosis. *Neurobiol. Dis.* **181**, 106113 (2023).
- 1427 45. Cooper, Y. A. *et al.* Functional regulatory variants implicate distinct transcriptional networks in dementia.  
1428 *Science* **377**, eabi8654 (2022).
- 1429 46. Steinberg, K. M. *et al.* Structural diversity and African origin of the 17q21.31 inversion polymorphism. *Nat.*  
1430 *Genet.* **44**, 872–880 (2012).
- 1431 47. Healy, D. G. *et al.* Tau gene and Parkinson’s disease: a case-control study and meta-analysis. *J. Neurol.*  
1432 *Neurosurg. Psychiatry* **75**, 962–965 (2004).
- 1433 48. Zabetian, C. P. *et al.* Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s  
1434 disease. *Ann. Neurol.* **62**, 137–144 (2007).
- 1435 49. Sánchez-Juan, P. *et al.* The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4  
1436 Non-carriers. *Front. Aging Neurosci.* **11**, 327 (2019).
- 1437 50. Jovanovic, M. *et al.* Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens.  
1438 *Science* **347**, 1259038 (2015).
- 1439 51. Emani, P. S. *et al.* Single-cell genomics and regulatory networks for 388 human brains. *Science* **384**,  
1440 eadi5199 (2024).
- 1441 52. Yang, A. C. *et al.* A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. *Nature* **603**,



- 1442 885–892 (2022).
- 1443 53. Hoffman, G. E. *et al.* Efficient differential expression analysis of large-scale single cell transcriptomics data  
1444 using dreamlet. *bioRxiv* (2023) doi:10.1101/2023.03.17.533005.
- 1445 54. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An Expanded View of Complex Traits: From Polygenic to  
1446 Omnigenic. *Cell* **169**, 1177–1186 (2017).
- 1447 55. Lyketsos, C. G. *et al.* Prevalence of neuropsychiatric symptoms in dementia and mild cognitive  
1448 impairment: results from the cardiovascular health study. *JAMA* **288**, 1475–1483 (2002).
- 1449 56. Bhattacharjee, A. *et al.* Cell type-specific transcriptional programs in mouse prefrontal cortex during  
1450 adolescence and addiction. *Nat. Commun.* **10**, 4169 (2019).
- 1451 57. Green, G. S. *et al.* Cellular dynamics across aged human brains uncover a multicellular cascade leading  
1452 to Alzheimer's disease. *bioRxiv* 2023.03.07.531493 (2023) doi:10.1101/2023.03.07.531493.
- 1453 58. Lee, D. *et al.* Plasticity of Human Microglia and Brain Perivascular Macrophages in Aging and Alzheimer's  
1454 Disease. *medRxiv* 2023.10.25.23297558 (2023) doi:10.1101/2023.10.25.23297558.
- 1455 59. Roussos, P. *et al.* Alzheimer's disease transcriptional landscape in ex-vivo human microglia. *Res Sq*  
1456 (2024) doi:10.21203/rs.3.rs-3851590/v1.
- 1457 60. Kitano, H. Computational systems biology. *Nature* **420**, 206–210 (2002).
- 1458 61. Bhembre, N., Bonthron, C. & Opazo, P. Synaptic Compensatory Plasticity in Alzheimer's Disease. *J.*  
1459 *Neurosci.* **43**, 6833–6840 (2023).
- 1460 62. Hernández-Ortega, K., Garcia-Esparcia, P., Gil, L., Lucas, J. J. & Ferrer, I. Altered Machinery of Protein  
1461 Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. *Brain Pathol.* **26**, 593–605 (2016).
- 1462 63. Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A. & Perry, G. Mitochondrial dysfunction is a trigger of  
1463 Alzheimer's disease pathophysiology. *Biochim. Biophys. Acta* **1802**, 2–10 (2010).
- 1464 64. Lee, J.-H. *et al.* Faulty autolysosome acidification in Alzheimer's disease mouse models induces  
1465 autophagic build-up of A $\beta$  in neurons, yielding senile plaques. *Nat. Neurosci.* **25**, 688–701 (2022).
- 1466 65. Butterfield, D. A. & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer  
1467 disease. *Nat. Rev. Neurosci.* **20**, 148–160 (2019).
- 1468 66. Mallach, A. *et al.* Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease

- 1469 mouse model, as revealed by spatial transcriptomics. *Cell Rep.* **43**, 114216 (2024).
- 1470 67. Marsh, S. E. *et al.* The adaptive immune system restrains Alzheimer's disease pathogenesis by  
1471 modulating microglial function. *Proceedings of the National Academy of Sciences* **113**, E1316–E1325  
1472 (2016).
- 1473 68. Grayson, J. M. *et al.* T cell exhaustion is associated with cognitive status and amyloid accumulation in  
1474 Alzheimer's disease. *Sci. Rep.* **13**, 15779 (2023).
- 1475 69. Su, W. *et al.* CXCR6 orchestrates brain CD8<sup>+</sup> T cell residency and limits mouse Alzheimer's disease  
1476 pathology. *Nat. Immunol.* **24**, 1735–1747 (2023).
- 1477 70. Haney, M. S. *et al.* APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia. *Nature*  
1478 **628**, 154–161 (2024).
- 1479 71. Marschallinger, J. *et al.* Lipid-droplet-accumulating microglia represent a dysfunctional and  
1480 proinflammatory state in the aging brain. *Nat. Neurosci.* **23**, 194–208 (2020).
- 1481 72. Claes, C. *et al.* Plaque-associated human microglia accumulate lipid droplets in a chimeric model of  
1482 Alzheimer's disease. *Mol. Neurodegener.* **16**, 50 (2021).
- 1483 73. Lee, D. *et al.* Plasticity of human microglia and brain perivascular macrophages in aging and Alzheimer's  
1484 disease. *bioRxiv* (2023) doi:10.1101/2023.10.25.23297558.
- 1485 74. Zhu, J., He, F., Hu, S. & Yu, J. On the nature of human housekeeping genes. *Trends Genet.* **24**, 481–484  
1486 (2008).
- 1487 75. Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. *Trends Genet.* **29**, 569–574  
1488 (2013).
- 1489 76. Jorstad, N. L. *et al.* Comparative transcriptomics reveals human-specific cortical features. *Science* **382**,  
1490 eade9516 (2023).
- 1491 77. Louveau, A. *et al.* Structural and functional features of central nervous system lymphatic vessels. *Nature*  
1492 **523**, 337–341 (2015).
- 1493 78. Ahn, J. H. *et al.* Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. *Nature* **572**, 62–66  
1494 (2019).
- 1495 79. Li, X. *et al.* Meningeal lymphatic vessels mediate neurotropic viral drainage from the central nervous

- 1496 system. *Nat. Neurosci.* **25**, 577–587 (2022).
- 1497 80. Fitzpatrick, Z. *et al.* Venous-plexus-associated lymphoid hubs support meningeal humoral immunity.  
1498 *Nature* **628**, 612–619 (2024).
- 1499 81. Da Mesquita, S. *et al.* Meningeal lymphatics affect microglia responses and anti-A $\beta$  immunotherapy.  
1500 *Nature* **593**, 255–260 (2021).
- 1501 82. Louveau, A. *et al.* CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic  
1502 vasculature. *Nat. Neurosci.* **21**, 1380–1391 (2018).
- 1503 83. Da Mesquita, S., Fu, Z. & Kipnis, J. The Meningeal Lymphatic System: A New Player in Neurophysiology.  
1504 *Neuron* **100**, 375–388 (2018).
- 1505 84. Da Mesquita, S. *et al.* Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease.  
1506 *Nature* **560**, 185–191 (2018).
- 1507 85. Long, J. M. & Holtzman, D. M. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.  
1508 *Cell* **179**, 312–339 (2019).
- 1509 86. Ryder, B. D., Wydorski, P. M., Hou, Z. & Joachimiak, L. A. Chaperoning shape-shifting tau in disease.  
1510 *Trends Biochem. Sci.* **47**, 301–313 (2022).
- 1511 87. Mok, S.-A. *et al.* Mapping interactions with the chaperone network reveals factors that protect against tau  
1512 aggregation. *Nat. Struct. Mol. Biol.* **25**, 384–393 (2018).
- 1513 88. Koren, J., 3rd *et al.* Chaperone signalling complexes in Alzheimer’s disease. *J. Cell. Mol. Med.* **13**, 619–  
1514 630 (2009).
- 1515 89. Saha, I. *et al.* The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a  
1516 cellular system. *Nat. Commun.* **14**, 560 (2023).
- 1517 90. Brigas, H. C. *et al.* IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s  
1518 disease. *Cell Rep.* **36**, 109574 (2021).
- 1519 91. Rosenzweig, N. *et al.* Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment  
1520 in Alzheimer’s disease. *Nat. Med.* (2024) doi:10.1038/s41591-024-03122-3.
- 1521 92. Cipollini, V., Anrather, J., Orzi, F. & Iadecola, C. Th17 and Cognitive Impairment: Possible Mechanisms of  
1522 Action. *Front. Neuroanat.* **13**, 95 (2019).

- 1523 93. Criado-Marrero, M. *et al.* Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged  
1524 wild-type mice. *Acta Neuropathol Commun* **9**, 65 (2021).
- 1525 94. Gorantla, N. V. & Chinnathambi, S. Tau Protein Squired by Molecular Chaperones During Alzheimer's  
1526 Disease. *J. Mol. Neurosci.* **66**, 356–368 (2018).
- 1527 95. Galea, I. The blood-brain barrier in systemic infection and inflammation. *Cell. Mol. Immunol.* **18**, 2489–  
1528 2501 (2021).
- 1529 96. Bennett, D. A. *et al.* Religious Orders Study and Rush Memory and Aging Project. *J. Alzheimers. Dis.* **64**,  
1530 S161–S189 (2018).
- 1531 97. Marquez, D. X. *et al.* Representation of Older Latinxs in Cohort Studies at the Rush Alzheimer's Disease  
1532 Center. *Neuroepidemiology* **54**, 404–418 (2020).
- 1533 98. Mirra, S. S. *et al.* The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II.  
1534 Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* **41**, 479–486  
1535 (1991).
- 1536 99. Bennett, D. A. *et al.* Neuropathology of older persons without cognitive impairment from two community-  
1537 based studies. *Neurology* **66**, 1837–1844 (2006).
- 1538 100. Bennett, D. A. *et al.* Natural history of mild cognitive impairment in older persons. *Neurology* **59**, 198–205  
1539 (2002).
- 1540 101. Bennett, D. A. *et al.* Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-  
1541 based cohort studies compared to standard practice in a clinic-based cohort study. *Neuroepidemiology* **27**,  
1542 169–176 (2006).
- 1543 102. Fullard, J. F. *et al.* Population-scale cross-disorder atlas of the human prefrontal cortex at single-cell  
1544 resolution.
- 1545 103. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).
- 1546 104. Borrell, L. N. *et al.* Race and Genetic Ancestry in Medicine - A Time for Reckoning with Racism. *N. Engl.*  
1547 *J. Med.* **384**, 474–480 (2021).
- 1548 105. Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* **82**,  
1549 239–259 (1991).


- 1550 106. Braak, H., Alafuzoff, I., Arzberger, T., Kretschmar, H. & Del Tredici, K. Staging of Alzheimer disease-  
1551 associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol.*  
1552 **112**, 389–404 (2006).
- 1553 107. Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer  
1554 disease: age categories from 1 to 100 years. *J. Neuropathol. Exp. Neurol.* **70**, 960–969 (2011).
- 1555 108. Stoeckius, M. *et al.* Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for  
1556 single cell genomics. *Genome Biol.* **19**, 224 (2018).
- 1557 109. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 1558 110. Kaminow, B., Yunusov, D. & Dobin, A. STARsolo: accurate, fast and versatile mapping/quantification of  
1559 single-cell and single-nucleus RNA-seq data. *bioRxiv* 2021.05.05.442755 (2021)  
1560 doi:10.1101/2021.05.05.442755.
- 1561 111. Huang, Y., McCarthy, D. J. & Stegle, O. Vireo: Bayesian demultiplexing of pooled single-cell RNA-seq  
1562 data without genotype reference. *Genome Biol.* **20**, 273 (2019).
- 1563 112. Li, B. *et al.* Cumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus  
1564 RNA-seq. *Nat. Methods* **17**, 793–798 (2020).
- 1565 113. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis.  
1566 *Genome Biol.* **19**, 15 (2018).
- 1567 114. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: Computational Identification of Cell Doublets in Single-  
1568 Cell Transcriptomic Data. *Cell Syst* **8**, 281–291.e9 (2019).
- 1569 115. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat. Methods*  
1570 **16**, 1289–1296 (2019).
- 1571 116. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**,  
1572 14049 (2017).
- 1573 117. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected  
1574 communities. *Sci. Rep.* **9**, 5233 (2019).
- 1575 118. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for Dimension  
1576 Reduction. *arXiv [stat.ML]* (2018).





- 1577 119. Xu, C. *et al.* Probabilistic harmonization and annotation of single-cell transcriptomics data with deep  
1578 generative models. *Mol. Syst. Biol.* **17**, e9620 (2021).
- 1579 120. Gayoso, A. *et al.* A Python library for probabilistic analysis of single-cell omics data. *Nat. Biotechnol.* **40**,  
1580 163–166 (2022).
- 1581 121. Virshup, I. *et al.* The scverse project provides a computational ecosystem for single-cell omics data  
1582 analysis. *Nat. Biotechnol.* **41**, 604–606 (2023).
- 1583 122. Kosoy, R. *et al.* Genetics of the human microglia regulome refines Alzheimer’s disease risk loci. *Nat.*  
1584 *Genet.* **54**, 1145–1154 (2022).
- 1585 123. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**,  
1586 290–299 (2021).
- 1587 124. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**,  
1588 2867–2873 (2010).
- 1589 125. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526**, 68–  
1590 74 (2015).
- 1591 126. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, (2021).
- 1592 127. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.  
1593 *Gigascience* **4**, 7 (2015).
- 1594 128. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression  
1595 and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 1596 129. Bowles, K. R. *et al.* 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are  
1597 associated with LRRC37A/2 expression in astrocytes. *Mol. Neurodegener.* **17**, 48 (2022).
- 1598 130. Browning, B. L., Tian, X., Zhou, Y. & Browning, S. R. Fast two-stage phasing of large-scale sequence  
1599 data. *Am. J. Hum. Genet.* **108**, 1880–1890 (2021).
- 1600 131. Hoffman, G. E. & Roussos, P. *Count Ratio Uncertainty Modeling Based Linear Regression.* (2024).  
1601 doi:10.5281/zenodo.12752107.
- 1602 132. Lähnemann, D. *et al.* Eleven grand challenges in single-cell data science. *Genome Biol.* **21**, 31 (2020).
- 1603 133. Crowell, H. L. *et al.* muscat detects subpopulation-specific state transitions from multi-sample multi-

- 1604 condition single-cell transcriptomics data. *Nat. Commun.* **11**, 6077 (2020).
- 1605 134. Squair, J. W. *et al.* Confronting false discoveries in single-cell differential expression. *Nat. Commun.* **12**,  
1606 5692 (2021).
- 1607 135. Zimmerman, K. D., Espeland, M. A. & Langefeld, C. D. A practical solution to pseudoreplication bias in  
1608 single-cell studies. *Nat. Commun.* **12**, 738 (2021).
- 1609 136. Murphy, A. E., Fancy, N. N. & Skene, N. G. Avoiding false discoveries: Revisiting an Alzheimer's disease  
1610 snRNA-Seq dataset. *bioRxiv* 2023.04.01.535040 (2023) doi:10.1101/2023.04.01.535040.
- 1611 137. Hoffman, G. E. & Roussos, P. Dream: powerful differential expression analysis for repeated measures  
1612 designs. *Bioinformatics* **37**, 192–201 (2021).
- 1613 138. Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. *Nucleic  
1614 Acids Res.* **40**, e133 (2012).
- 1615 139. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-  
1616 wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 1617 140. Chia, R. *et al.* Genome sequencing analysis identifies new loci associated with Lewy body dementia and  
1618 provides insights into its genetic architecture. *Nat. Genet.* **53**, 294–303 (2021).
- 1619 141. Ferrari, R. *et al.* Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet  
1620 Neurol.* **13**, 686–699 (2014).
- 1621 142. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal  
1622 ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
- 1623 143. Bendall, S. C. *et al.* Single-cell trajectory detection uncovers progression and regulatory coordination in  
1624 human B cell development. *Cell* **157**, 714–725 (2014).
- 1625 144. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling for single-cell  
1626 transcriptomics. *Nat. Methods* **15**, 1053–1058 (2018).
- 1627 145. Loshchilov, I. & Hutter, F. Decoupled Weight Decay Regularization. *arXiv [cs.LG]* (2017).
- 1628 146. Idrissi, B. Y., Arjovsky, M., Pezeshki, M. & Lopez-Paz, D. Simple data balancing achieves competitive  
1629 worst-group-accuracy. *arXiv [cs.LG]* (2021).
- 1630 147. Wang, J. Z., Du, Z., Payattakool, R., Yu, P. S. & Chen, C.-F. A new method to measure the semantic

1631 similarity of GO terms. *Bioinformatics* **23**, 1274–1281 (2007).










AD  
comorbidity











All Subdivisions


Neurons Only








NPD NDD






NPD NDD













































Absolute logFC by Assay and Trait



















## Standard training




## Equal sampling















a



b

